ПРИМЕНЕНИЕ ПРОСОМАТОСТАТИНА В ДИАГНОСТИКЕ

FIELD: medicine. SUBSTANCE: group of inventions refers to medicine and concerns a method for diagnosing and monitoring disturbed activity and/or function of the gastrointestinal tract, except for somatostatinoma, in the patients, wherein the method involves the stages of sampling physiological fluid in the patient, measuring prosomatostatin 1-64 or its fragments in the above sample, correlating prosomatostatin 1-64 or its fragments to the diagnosis of disturbed activity and/or function of the gastrointestinal tract, except for somatostatinoma, determined in the above patient. The group of inventions also concerns a kit for measuring prosomatostatin 1-64 or its fragments comprising at least two antibodies. The group of invention provides diagnosing and monitoring disturbed activity and/or function of the gastrointestinal tract specified in a group consisting of Crohn's disease, pancreatitis, diverticulitis, pancreatic carcinoma, pancreatic neocarcinoma, oesophageal carcinoma, gastric carcinoma, colonic carcinoma or colonic neocarcinoma. EFFECT: improving the method for diagnosing and monitoring disturbed activity and/or function of the gastrointestinal tract. 10 cl, 9 dwg, 1 tbl, 1 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК G01N 33/68 (13) 2 573 985 C2 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2013157959/15, 31.05.2012 (24) Дата начала отсчета срока действия патента: 31.05.2012 (72) Автор(ы): ШТРУК Йоахим (DE) (73) Патентообладатель(и): Б.Р.А.Х.М.С. ГМБХ (DE) Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 20.07.2015 Бюл. № 20 R U 07.06.2011 EP 11004636.4 (45) Опубликовано: 27.01.2016 Бюл. № 3 C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 09.01.2014 (86) Заявка PCT: 2 5 7 3 9 8 5 EP 2012/002313 (31.05.2012) R U 2 5 7 3 9 8 5 (56) Список документов, цитированных в отчете о поиске: LEPAGE-LEZIN A., et al., Prosomatostatin is processed in ...

ПРИМЕНЕНИЕ ЭНТЕРОВИРУСОВ ДЛЯ ДИАГНОСТИКИ, ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ

... 1. Способ диагностики связанного с глютеном заболевания, включающий взятие образца у субъекта и определение присутствия энтеровируса в этом образце, причем присутствие энтеровируса указывает на названное заболевание. ! 2. Способ по п.1, включающий определение компонентов энтеровируса в образце. ! 3. Способ по п.2, в котором указанный компонент является белком, пептидом или нуклеиновой кислотой. ! 4. Способ по п.1, включающий определение энтеровируса иммуногистохимически. ! 5. Способ по п.1, включающий определение энтеровируса гибридизацией in situ. ! 6. Способ по п.1, включающий определение энтеровируса посредством проведения реакции РТ-ПЦР. ! 7. Способ по п.1, включающий определение энтеровируса методом NASBA или путем выявления вируса в клеточной культуре. ! 8. Применение энтеровируса, или его компонента, или антитела против указанного вируса или компонента для производства вакцины против связанного с глютеном заболевания. !9. Применение по п.8, в котором вакцина включает различные комбинации ...

PROGNOSTISCHE ALLERGIE- ODER ENTZÜNDUNGSTEST

PROCEDURE FOR THE DIAGNOSIS OF IMMUNOLOGICAL FOOD SENSITIVITY

MORE PROGNOSTICALLY ALLERGY OR ENTZUNDUNGSTEST

Peptide microarrays and novel biomarkers for celiac disease

The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., celiac disease. Furthermore, a set of novel biomarkers for celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers.

Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity

Peptide microarrays and novel biomarkers for celiac disease

The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., celiac disease. Furthermore, a set of novel biomarkers for celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers.

POLYPEPTIDE AND ANTIBODY BOUND TO POLYPEPTIDE

An antibody for being specifically bound to a pro brain-derived neurotrophic factor (pro-BDNF) and a bound epitope. The antibody and the protein are used for treating autoimmune diseases. By inhibiting the activity induced by the pro-BDNF, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephriti, chronic obstructive pulmonary diseases, asthma or cystic fibrosis, multiple sclerosis and other autoimmune diseases are treated.

USE OF MIC-1 OR MODULATING AGENT THEREOF TO MODULATE APPETITE OR BODY WEIGHT

... ²The present invention provides a method of modulating appetite and/or body ²weight in a ²subject, said method comprising administering to said subject an effective ²amount of ²M1C-1 modulating agent, wherein said agent increases or decreases the amount ²of ²M1C-1 present in said subject, or enhances the biological activity of M1C-1 ²present in ²said subject.²² ...

METHOD FOR DETERMINING THE DISTINCTIVE NUTRITIONAL REQUIREMENTS OF A PATIENT

The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

Use of product from plants comprising extracts, fractions and/or molecules as TGR5 specific agonist, for human or animal the preparation of drug to prevent and/or treat metabolic disorder, obesity and type II diabetes

Use of a product from plants comprising extracts, fractions and/or molecules as G-protein coupled receptor (TGR5) specific agonist, having minimum effective concentration (EC50) of greater/equal to TGR5 natural ligand comprising litocholic acid, not activate the farnesoid X receptor (FXR) nuclear receptor, inducing a reduction of weight gain induced by a fatty food to a model, who has metabolic syndrome, and a reduction of mass of fatty cell of epididymis in the models, and inducing a improvement of glucose tolerance, is claimed. Use of a product from plants comprising extracts, fractions and/or molecules as G-protein coupled receptor (TGR5) specific agonist, where the plant extract or fraction is obtained from the extract or the molecules is obtained by the extract or fractions, having minimum effective concentration (EC50) of greater or equal to TGR5 natural ligand, such as litocholic acid, not activate the farnesoid X receptor (FXR) nuclear receptor, inducing a reduction of weight gain induced by a fatty food to a model, who has metabolic syndrome, as well as a reduction of mass of fatty cell of epididymis in the models, and inducing a improvement of glucose tolerance, is claimed. ACTIVITY : Metabolic; Anorectic; Antidiabetic. MECHANISM OF ACTION : G-protein coupled receptor agonist. Tests details are described but no results given.

AGENTS AND METHODS FOR MODULATING MACROPHAGE INHIBITORY CYTOKINE (MIC-1) ACTIVITY

The invention relates to a method and novel types of agents for modulating appetite and/or body weight in a subject. Moreover, the invention relates to a method of screening for agents which interact and modulate the activity of the receptor complex for macrophage inhibitory cytokine-1 (MIC-1).

MODULATION OF ADIPOSE TRIGLYCERIDE LIPASE FOR PREVENTION AND TREATMENT OF CACHEXIA, LOSS OF WEIGHT AND MUSCLE ATROPHY AND METHODS OF SCREENING THEREFOR

The present invention relates to agents, and methods for identifying compounds, which agents and compounds are effective in the treatment, and more particularly, that inhibit cachexia, and its associated or related disorders and conditions. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by cachexia, and its associated or related disorders and conditions and/or cachexia, and its associated or related disorders and conditions, such as for example, cancer cachexia and cachexia associated with AIDS, autoimmune disorders, drug addiction, alcoholism, chronic inflammatory disorders, cirrhosis of the liver, anorexia and neurodegenerative disease. In particular, the diagnostic marker and drug target of the invention is the ATGL Lipase, which can be inhibited by e.g. siRNAs and compounds with any of the following structures (I).

ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3 AND USES THEREOF

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25- hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.

Method of Evaluating Nutriture

An aspect of the disclosure provides a method of evaluating the nutriture of a subject, comprising (1) calculating the ratio of the 13CO2 amount to the unlabeled CO2 amount or total CO2 amount in an expired air sample obtained from the subject to which a 13C-labeled amino acid was administered; and (2) comparing the ratio with a reference value to evaluate the nutriture. Another aspect of the disclosure provides a composition comprising a 13C-labeled amino acid for evaluating the nutriture of a subject.

Methods for assessing ability of ingestible substances to cause inflammation

Assays and apparatuses for assessing the ability of certain orally-ingestible samples, such as saliva or foodstuffs to cause inflammation. The assay comprising analysing the concentration of a Toll-like receptor (TLR) stimulant or a nucleotide-binding oligomerisation domain (NOD) like receptor (NLR) stimulant in an orally ingestible sample and comparing the concentration with a reference concentration known to represent inflammation risk, wherein an increased concentration of TLR-stimulant or NLR-stimulant in the sample compared to the reference concentration indicates that the sample causes inflamation. The stimulants may be a pathogen associated molecular pattern (PAMP), e.g. lipopolysaccharide (LPS), bacterial lipopeptide, flagellin, unmethylated DNA, bacterial peptidoglycan or a microbe associated molecular pattern (MAMP). Also claimed is the use of a TLR signalling inhibitor (e.g. oxidised palmitoyl-arachidonyl phosphocholine (OxPAPC), Polymyxin B (PMB) or siRNA) for reducing or pre-empting the risk of inflammation.

Compositions, devices, and methods of fibromyalgia sensitivity testing

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤ 0.07 as determined by their raw p-value or an average discriminatory p-value of ≤ 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

Novel anti-aging agents and methods to identify them

The present invention discloses novel mechanisms in the aging process and describes novel methods for high-throughput screening to identify, detect, and purify agents to be used for improving mitochondrial function, maintaining the cell cycle- arrested state in senescent and post mitotic cells, and thus preventing or treating age- related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions identified from this method. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders.

Peptide microarrays and novel biomarkers for celiac disease

The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., celiac disease. Furthermore, a set of novel biomarkers for celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers.

COMPOSITIONS, DEVICES, AND METHODS OF FIBROMYALGIA SENSITIVITY TESTING

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of = 0.07 as determined by their raw p-value or an average discriminatory p-value of = 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

PROGNOSTIC ALLERGY OR INFLAMMATION TEST

One can predict the likelihood a child will outgrow an allergy, especially a food allergy, by screening for IgE antibodies immunoreactivities with linear versus conformational epitopes. The child is first screened using standard techniques to determine what antigens the child is allergic to. The immunoglobulins in the sample from the patient are then characterised either using the natural purified antigen, recombinant antigen, reduced and alkylated antigen, proteolytic fragments of the antigen or synthetic peptides of between 4 and 40 amino acids in length, which can be immobilised for rapid and accurate screening. The antibodies from the patient are reacted with the protein or peptides to determine which peptides are bound by the antibodies. These antibodies are then characterised to determine if the epitopes they bind are linear or conformational. Those patients having antibodies primarily reactive with conformational epitopes will typically outgrow their allergies. A similar method for evaluation of IgG antibodies can be used to predict the prognosis of certain inflammatory disorders.

COMPOSITIONS, DEVICES, AND METHODS OF OSTEOARTHRITIS SENSITIVITY TESTING

Contemplated test kits and methods for food sensitivity related to osteoarthritis are based on rational-based selection of food preparations with established discriminatory p-value. In some embodiments, kits include those with a minimum number of food preparations that have an average discriminatory p-value of = 0.07 as determined by their raw p-value or an average discriminatory p-value of = 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

НОВЫЕ ВЕЩЕСТВА, ПРЕПЯТСТВУЮЩИЕ СТАРЕНИЮ, И СПОСОБЫ ИХ ИДЕНТИФИКАЦИИ

В изобретении раскрыты новые механизмы процесса старения, а также описаны новые способы скрининга высокой производительности для идентификации, обнаружения и очищения веществ, которые предназначены для использования с целью улучшения функции митохондрий и контроля старения при блокированном клеточном цикле в стареющих и постмитотических клетках, что обеспечивает профилактику или лечение возрастных заболеваний или нарушений, связанных с прогрессированием ухудшения функции митохондрий, дисфункцией теломер и/или ухудшением состояния при блокированном росте. В настоящем изобретении также раскрыт ряд веществ или смесей, которые были идентифицированы в результате применения данного способа. Также в настоящем изобретении предлагается использовать рапамицин или его аналоги в низких дозах для имитации ограничения калорийности питания в целях предотвращения возрастных заболеваний или нарушений.

DERMATOPONTIN AS A THERAPEUTIC FOR METABOLIC DISORDERS

BIOLOGICALLY ACTIVE COMPOSITIONS, METHODS FOR PRODUCING THE SAME AND BIOLOGICAL APPLICATIONS

The invention relates to compositions and products that can be obtained from plants, such as extracts, fractions and/or molecules. They can be used in the production of drugs for human beings or animals, essentially for preventing or treating metabolic disorders, obesity and/or diseases associated therewith such as the X syndrome (metabolic syndrome), type-2 diabetes, or for producing food additives for human beings or animals.

COMPOSITIONS AND METHODS FOR MODULATING DESNUTRIN-MEDIATED ADIPOCYTE LIPOLYSIS

The present disclosure provides methods of converting white adipose tissue to brown adipose tissue in an individual, generally involving modulating desnutrin-mediated lipolysis in adipocytes in the individual. The present disclosure further provides methods for treating obesity. The present disclosure further provides methods of identifying an agent that increases the level and/or activity of desnutrin in an adipocyte.

BREATH KETONE DETECTOR

Ketoacidosis is an extreme and uncontrolled form of ketosis, which is a normal response to prolonged fasting. Embodiments of this in vention test the ketone level of a patient by measuring the ketone bodies in breath condensation. Some embodiments include a device for medical testing comprising a hollow container, comprising powder mixture of sodium nitroferricyanide, ammonium sulfate and silica and a liquid including an ammonium hydroxide solution.

Methods for detecting vitamin C by mass spectrometry

Provided are methods for determining the amount of vitamin C in a sample using mass spectrometry. The methods generally involve ionizing vitamin C in a sample and detecting and quantifying the amount of the ion to determine the amount of vitamin C in the sample.

Method for interpreting tandem mass spectrometry data for clinical diagnosis

A method for interpreting data that is produced after a group of amino acids and acylcarnitines are derivatized from blood spots taken from newborn babies and scanned by a tandem mass spectrometer. Concentration levels of each metabolite, which are directly proportional to the butyl ester fragment after derivatization, are compared to threshold flags for determining a significance of any deviation of the metabolite relative to the flag threshold. The threshold flags are diagnostic limits to the data retrieved from each blood spot. The data includes metabolite concentrations and molar ratios of metabolites with other metabolites. Samples are labeled normal for a disease if the concentration of any of the metabolite concentrations or molar ratio concentration do not deviate from the flag threshold, but, in contrast, the sample must be further evaluated if a value is elevated or deficient to some degree. Thus, as each metabolite fragments at a different mass to charge value (m/z), corresponding ...

Leptin-related peptides

The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass.

Therapeutic Agents

A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.

Prognostic allergy test

One can predict the likelihood a child will outgrow an allergy, especially a food allergy, by screening for IgE antibodies immunoreactivities with linear versus conformational epitopes. The child is first screened using standard techniques to determine what antigens the child is allergic to. The immunoglobulins in the sample from the patient are then characterised either using the natural purified antigen, recombinant antigen, reduced and alkylated antigen, proteolytic fragments of the antigen or synthetic peptides of between 4 and 40 amino acids in length, which can be immobilised for rapid and accurate screening. The antibodies from the patient are reacted with the protein or peptides to determine which peptides are bound by the antibodies. These antibodies are then characterised to determine if the epitopes they bind are linear or conformational. Those patients having antibodies primarily reactive with conformational epitopes will typically outgrow their allergies. A similar method for ...

ПРИМЕНЕНИЕ ПРОСОМАТОСТАТИНА В ДИАГНОСТИКЕ

1. Способ диагностики, прогноза, мониторинга и оценки риска развития у пациентов нарушения активности и/или функции желудочно-кишечного тракта, и/или нарушения режима питания, за исключением соматостатиномы, где указанный способ включает стадии:i) взятия образца физиологической жидкости у пациента;ii) определения уровня просоматостатина 1-64 (SEQ ID NO: 6) или его фрагментов в указанном образце;iii) определения корреляции уровня просоматостатина 1-64 (SEQ ID NO: 6) или его фрагментов с диагнозом, прогнозом, мониторингом и оценкой риска развития у указанного пациента нарушения активности и/или функции желудочно-кишечного тракта и/или нарушения режима питания, за исключением соматостатиномы,где указанные фрагменты имеют длину по меньшей мере в 6 аминокислотных остатков.2. Способ по п. 1, где указанный образец физиологической жидкости берут у указанного пациента после голодания по меньшей мере в течение 8 часов.3. Способ по п. 1, где указанный пациент страдает заболеванием желудочно-кишечного тракта, характеризующимся нарушениями активности и/или функции желудочно-кишечного тракта и/или нарушениями режима питания, выбранными из группы, включающей воспалительные, инфекционные, органические и функциональные заболевания желудочно-кишечного тракта.4. Способ по п. 3, где указанное инфекционное заболевание желудочно-кишечного тракта вызвано вирусами, бактериями или кишечными паразитами.5. Способ по п. 3, где указанное воспалительное заболевание желудочно-кишечного тракта выбрано из группы, включающей воспалительное заболевание кишечника, включая болезнь Крона и язвенный колит, панкреатит, аппендицит и глютеновую болезнь.6. Способ по

TEST TO THE FORECAST OF ALLERGIES

METHODS FOR DIAGNOSING AND TREATMENT OF CONDITIONS THAT ALTER PHOSPHATE TRANSPORT IN MAMMALS

Tetrahydro-isoalpha acid compositions and methods for weight management

Compositions and methods to promote or maintain weight loss utilizing tetrahydro-isoalpha acid compounds are disclosed. Methods to increase synthesis of GLP-1 are disclosed.

A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway

Method for determining the distinctive nutritional requirements of a patient

The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

MODULATION OF PERIPHERAL CLOCKS IN ADIPOSE TISSUE

Genes encoding the transcription factors controlling the core circadian oscillator (BMAL, Clock, NPAS, Per) and their regulatory targets (Rev-erba, Rev-erb) have been found in adipose tissue. The circadian pattern of these genes was entrained using restricted feeding. The circadian gene expression profiles were examined in mice and in undifferentiated and adipocyte- differentiated human adipose stem cells following exposure to nuclear hormone receptor ligands (dexamethasone or thiazolidinedione) or 30% fetal bovine serum. All three agents induced the initiation of a cyclic expression profile in representative circadian genes in the human adipose stem cells. The circadian genes studied displayed an oscillatory expression profile, characterized by both a zenith and nadir within a 24-28 hr phase. The circadian gene pattern has been lengthened with use of an inhibitor of glycogen synthase kinase 3 beta. Modulation of the circadian pattern to lengthen or shorten can be used to affect weight ...

INDOXYL SULFATE AS A BIOMARKER OF PREBIOTIC EFFICACY FOR WEIGHT GAIN PREVENTION

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.

MIC-1 inhibiting agent

PEPTIDES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR CELIAC SPRUE

Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses.

METABOLITE MARKERS FOR WEIGHT MANAGEMENT

The present invention provides methods of using certain metabolite markers for predicting weight development or its related conditions of a subject. The present invention also provides compositions and kits useful for detecting metabolite markers of the present invention.

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system. 1. A method of preventing or treating body wasting in a human patient with traumatic brain injury , the method comprising:receiving a blood lactate concentration of the patient, from a lactate analyzer that has analyzed a blood sample of the patient, the blood lactate concentration received directly from the lactate analyzer or indirectly from the lactate analyzer over a network; andbased on the received blood lactate concentration of the patient, if the blood lactate concentration is less than about 2.0 mM, administering a nutritional support to the patient.2. The method of wherein the nutritional support comprises a gluconeogenic precursor or a monocarboxylic compound or both.3. The method of wherein the nutritional support comprises one or more salts.4. The method of wherein the nutritional support comprises a molecular label.5. The method of wherein the nutritional support has a milliosmolality of less than about 1000.6. The method of wherein the nutritional support comprises an amino acid.7. The method of wherein the nutritional support comprises one or more of the following: glycerol claim 1 ...

Kit and method for detecting food allergies

A method for detection of food allergies, by determining the presence of antibodies against specific antigens in a stool sample, involves diluting the specimen, introducing the diluted specimen to a substrate containing food antigens, and visually detecting a reaction.

QUANTIFICATION OF THE CARNITINSPIEGELS WITH DIALYSIS PATIENT

Methods for the fractionation of proteins

The present invention provides methods for the fractionation of low molecular weight proteins from mixed protein populations, and proteins obtained by said methods. The methods described herein may find application in, but are not limited to, the detection and/or quantitation of low abundance and/or low molecular weight proteins in biological samples.

Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.

USE OF ENTEROVIRUS FOR DIAGNOSTICS, TREATMENT AND PREVENTION OF DISEASE

The invention is based on the finding that enterovirus is present in body samples of patients with celiac disease. The invention opens up the possibility for using enteroviruses in diagnosing, preventing, treating and monitoring the treatment of celiac-related diseases. The invention relates to a method for diagnosing, treating and monitoring the treatment of a celiac-related disease. The invention also relates to the use of enteroviruses or components or antibodies thereof for producing a vaccine, and the use of anti-enterovirus compositions for preparing a pharmaceutical against said disease.

COMPOSITIONS, DEVICES, AND METHODS OF GASTROESOPHAGEAL REFLUX DISEASE SENSITIVITY TESTING

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of = 0.07 as determined by their raw p-value or an average discriminatory p-value of = 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME

The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders including diabetes-related disorders, Metabolic Syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.

METHODS FOR DIAGNOSING AND TREATING BODY WEIGHT RELATED DISORDERS IN ANIMALS

A method for determining if an animal is at risk for a body weight related disorder is described. An animal is provided and an aspect of ICAM receptor or .beta.2 integrin metabolism or structure is evaluated in the animal. An abnormality in the aspect of ICAM receptor or .beta.2 integrin metabolism or structure is diagnosed of being at risk for a body weight related disorder. Also described are methods for detecting the presence of a disease affecting body weight, methods for evaluating an agent for use in modulating body weight, methods for treating a body weight related disorder, methods for monitoring a therapeutic treatment of a disease affecting body weight, and methods for increasing the fat content in the liver or milk of an animal. Pharmaceutical compositions are also provided.

ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3 AND USES THEREOF

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25- hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.

LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME

The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders — including diabetes-related disorders, Metabolic Syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders — using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.

DIAGNOSTIC USE OF PROSOMATOSTATIN

The present invention relates to a method for the diagnosis, prognosis, monitoring and risk assessment of disturbances of the gastrointestinal tract activity and/or function and/or disturbances of the nutritional condition, with the exception of somatostatinoma, in a patient comprising the steps of: providing a sample of a bodily fluid of a patient; determining the level of proSomatostatin 1 -64 or fragments thereof in said sample; correlating the level of proSomatostatin 1 -64 or fragments thereof to the diagnosis, prognosis and risk assessment of disturbances of the gastrointestinal tract activity and/or function and/or disturbances of the nutritional condition, with the exception of somatostatinoma, in said patient, wherein said fragments have a length of at least 6 amino acid residues. The invention also relates to an antibody and a kit containing at least two antibodies.

PEPTIDES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR CELIAC SPRUE

Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses.

СПОСОБ ПОЛУЧЕНИЯ ФАКТОРА, СВЯЗАННОГО С КОНТРОЛЕМ НАД ПОТРЕБЛЕНИЕМ ПИЩИ И/ИЛИ МАССОЙ ТЕЛА, ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ АКТИВНОСТЬЮ ПОДАВЛЕНИЯ ПОТРЕБЛЕНИЯ ПИЩИ И/ИЛИ ПРИБАВЛЕНИЯ В ВЕСЕ, МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ, КОДИРУЮЩАЯ ПОЛИПЕПТИД, СПОСОБЫ И ПРИМЕНЕНИЕ ПОЛИПЕПТИДА

FIELD: medicine. SUBSTANCE: elaborated is method of obtaining factor, which takes part in process of control of appetite and/or body weight. Also described are genes, obtained by said method, polypeptides, coded by said genes, intended for treatment, control or diagnostics of diseases, associated with eating disorders and/or control of body weight. Invention also relates to substances, which inhibit activity of said genes or said polypeptides, intended for treatment, control or diagnostics of diseases, associated with process of appetite and/or body weight control. EFFECT: using tiasolidindions, possessing PPARγ-agonistic activity, it is possible to obtain genes and polypeptides, involved into regulation of appetite and/or body weight reduction. 27 cl, 41 dwg, 35 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 418 002 (13) C2 (51) МПК C07K C12N C12N A61K C07K A01K C12Q ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ 14/47 15/12 15/63 38/22 16/00 67/027 1/68 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) ИЗОБРЕТЕНИЯ К ПАТЕНТУ (72) Автор(ы): МОРИ Масатомо (JP), СИМИЗУ Хироюки (JP), ЕГУТИ Хироси (JP), ЯМАМОТО Масанори (JP) (21)(22) Заявка: 2008102731/10, 23.06.2006 (24) Дата начала отсчета срока действия патента: 23.06.2006 2 4 1 8 0 0 2 R U (56) Список документов, цитированных в отчете о поиске: SATOH T. et al. "Activation ofperoxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells", Oncogene. 2002 Mar 28;21(14):2171-80. BARNIKOL-WATANABE S. et al. "Human protein NEFA, a novel DNA binding/EFhand/leucine zipper protein. Molecular cloning and (см. прод.) (85) Дата начала рассмотрения заявки PCT на национальной фазе: 24.01.2008 (86) Заявка PCT: JP 2006/313041 (23.06.2006) (87) Публикация заявки РСТ: WO 2006/137597 (28.12.2006) Адрес для переписки: 103735, Москва, ул. Ильинка, 5/2, ООО "Союзпатент", пат.пов. А.Ю.Соболеву ...

НОВОЕ БИОЛОГИЧЕСКОЕ ВЕЩЕСТВО НЕСФАТИН, РОДСТВЕННЫЕ ЕМУ ВЕЩЕСТВА И ИХ ПРИМЕНЕНИЕ

... 1. Способ получения фактора, связанного с контролем над потреблением пищи и/или массой тела, содержащий следующие этапы: ! воздействие соединения тиазолидиндиона, имеющего PPARγ-агонистическую аткивность, на клетку млекопитающего, и ! получение генов, экспрессия которых индуцирована указанным соединением, и селекция и идентификация гена, кодирующего белок, содержащий сигнальный пептид из указанных полученных генов. ! 2. Полипептид, состоящий из аминокислотной последовательности, указанной в любой из SEQ ID NO:13-15, 39-41, 65-73, 101-103 или 107-115. ! 3. Полипептид, имеющий активность подавления потребления пищи и/или подавления прибавления в весе, содержащий аминокислотную последовательность, имеющую гомологию, по меньшей мере, в 60% с аминокислотной последовательностью, указанной в любой из SEQ ID NO:13-15, 39-41, 65-73, 101-103 и 107-115; или аминокислотную последовательность, в которой некоторые из аминокислот удалены, вставлены или заменены в аминокислотной последовательности, указанную ...

Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25- hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.

Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25 hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample. - 77 -

Leptin-related peptides

LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME

The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders including diabetes-related disorders, Metabolic Syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.

MODULATION OF PERIPHERAL CLOCKS IN ADIPOSE TISSUE

Genes encoding the transcription factors controlling the core circadian oscillator (BMAL, Clock, NPAS, Per) and their regulatory targets (Rev-erba, Rev-erb) have been found in adipose tissue. The circadian pattern of these genes was entrained using restricted feeding. The circadian gene expression profiles were examined in mice and in undifferentiated and adipocyte-differentiated human adipose stem cells following exposure to nuclear hormone receptor ligands (dexamethasone or thiazolidinedione) or 30% fetal bovine serum. All three agents induced the initiation of a cyclic expression profile in representative circadian genes in the human adipose stem cells. The circadian genes studied displayed an oscillatory expression profile, characterized by both a zenith and nadir within a 24-28 hr phase. The circadian gene pattern has been lengthened with use of an inhibitor of glycogen synthase kinase 3 beta. Modulation of the circadian pattern to lengthen or shorten can be used to affect weight gain ...

Method of measuring ceruloplasmin concentration in a blood spot, kit and method of diagnosing Wilson's disease

The present invention relates to a method for measuring a ceruloplasmin concentration, and more particularly, to a method for measuring a ceruloplasmin in a blood spot based on a standard concentration curve obtained through an enzyme-linked immunosorbent assay (ELISA) or a dissociation-enhanced time-resolved fluoroimmunoassay using a ceruloplasmin-specific polyclonal antibody or a ceruloplasmin-specific monoclonal antibody.

Methods for selective detection of biologically relevant acids

Methods and systems for performing ion mobility spectrometry are provided herein. In accordance with various aspects of the applicant's teachings, the methods and systems can provide for the separation of biologically relevant acids that may be difficult to separate with conventional MS techniques. In various aspects, methods and systems in accordance with applicant's teachings can enable a differential mobility spectrometer to resolve biologically relevant acids through the use of CO2 as the drift gas in combination with Acetone.

Assay for determining the risk of a toll-like receptor containing foodstuff for causing systemic inflammation in vivo

Compositions, devices, and methods of gastroesophageal reflux disease sensitivity testing

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤ 0.07 as determined by their raw p-value or an average discriminatory p-value of ≤ 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

METHOD FOR MODULATING APPETITE

ABSTRACT The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.

PROGNOSTIC ALLERGY OR INFLAMMATION TEST

One can predict the likelihood a child will outgrow an allergy, especially a food allergy, by screening for IgE antibodies immunoreactivities with linear versus conformational epitopes. The child is first screened using standard techniques to determine what antigens the child is allergic to. The immunoglobulins in the sample from the patient are then characterised either using the natural purified antigen, recombinant antigen, reduced and alkylated antigen, proteolytic fragments of the antigen or synthetic peptides of between 4 and 40 amino acids in length, which can be immobilised for rapid and accurate screening. The antibodies from the patient are reacted with the protein or peptides to determine which peptides are bound by the antibodies. These antibodies are then characterised to determine if the epitopes they bind are linear or conformational. Those patients having antibodies primarily reactive with conformational epitopes will typically outgrow their allergies. A similar method for ...

USE OF MIC-1 OR MODULATING AGENT THEREOF TO MODULATE APPETITE OR BODY WEIGHT

The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of M1C-1 modulating agent, wherein said agent increases or decreases the amount of M1C-1 present in said subject, or enhances the biological activity of M1C-1 present in said subject.

Method for detection of lactose intolerance and/or lactose malabsorption in human organism, involves combining obtained values by function to obtain end value based on score of symptoms and score of intensity of pain on hypogastrium level

La présente invention a trait à un kit de diagnostic et un procédé de détection de la malabsorption et/ou de l'intolérance au lactose.

MIC-1 INHIBITING AGENT

USE OF ENTEROVIRUS FOR DIAGNOSTICS, TREATMENT AND PREVENTION OF DISEASE

The invention is based on the finding that enterovirus is present in body samples of patients with celiac disease. The invention opens up the possibility for using enteroviruses in diagnosing, preventing, treating and monitoring the treatment of celiac-related diseases. The invention relates to a method for diagnosing, treating and monitoring the treatment of a celiac-related disease. The invention also relates to the use of enteroviruses or components or antibodies thereof for producing a vaccine, and the use of anti-enterovirus compositions for preparing a pharmaceutical against said disease.

METHOD AND USE OF CIRCULATING LEVELS OF ENDOCANNABINOID LIGANDS FOR THE DETERMINATION OF PATIENT IN NEED AND/OR SUITABLE FOR CB1R ANTAGONIST DRUG TREATMENT AS WELL AS METHOD FOR INDUCING WEIGHT LOSS/MAINTENANCE/GAIN

The present invention relates to patient selection tools and methods (including personalised medicine). In particular, the present invention permits the im proved selection of a patient in need of treatment with a cannabinoid re ceptor (CB1R) antagoni st drug, based on the levels of circulating endogenous cannabinoi d ligands (endocannabi noids). One of the aspects of the invention is a method of select ing a mammal in need of weight loss and/or weight maintenance and/or pr evention of weight gain treatment with a CB1R antagonist drug which comprises determining the leve l of at least one circulating endogenous cannabinoid ligand in the mamma l, whereby to predict an in creased likelihood of response to the CB1R antagonist drug. Some of the benefits of this personalised medicine approach include the ability to identify patients that are more likely to respond favourably to CB1R antagonist drug treatment and to identify pa tients less likely to respond to the drug treatment thus avoiding ...

METHOD FOR DIAGNOSING IMMUNOLOGIC FOOD SENSITIVITY

The invention includes novel methodology for diagnosing immunologic food or drug sensitivities. The method for diagnosing food sensitivities includes using diagnoses of other related disorders, such as microscopic colitis or other chronic immunologic/autoimmune syndromes, chronic diarrhea, irritable bowel syndrome, and hepatitis C and other hepatic diseases, Crohn's disease, alcoholism, and other idiopathic neuropsychiatric and neurologic disorders, as indicators in the diagnosis of the food sensitivity. Additionally, failure to respond to or a relapse after treatment for microscopic colitis with bismuth subsalicylate is disclosed by the present invention as being a further indicator in the diagnosis of immunologic food sensitivity. Finally, the presence of certain HLA-DQ alleles, particularly HLA-DQ1,3; -DQ1,7; -DQ1,8; and -DQ1,9, HLA-DQ1,1, and at least two subtypes of the HLA-DQ1 allele identified by molecular analysis as HLA-DQB1*0501 and HLA-DQB1*0602, as indicators in diagnosing immunologic ...

Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity

The present invention relates to agents, and methods for identifying compounds, which agents and compounds are effective in the treatment, and more particularly, that inhibit cachexia, and its associated or related disorders and conditions. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by cachexia, and its associated or related disorders and conditions and/or cachexia, and its associated or related disorders and conditions, such as for example, cancer cachexia and cachexia associated with AIDS, autoimmune disorders, drug addiction, alcoholism, chronic inflammatory disorders, cirrhosis of the liver, anorexia and neurodegenerative disease. In particular, the diagnostic marker and drug target of the invention is the ATGL Lipase, which can be inhibited by e.g. siRNAs and compounds with any of the following structures (I).

Method for interpreting tandem mass spectrometry data for clinical diagnosis of genetic disorders such as citrullinemia

A method for interpreting data that is produced after a group of amino acids and acylcarnitines are derivatized from blood spots taken from newborn babies and scanned by a tandem mass spectrometer. Concentration levels of each metabolite, which are directly proportional to the butyl ester fragment after derivatization, are compared to threshold flags for determining a significance of any deviation of the metabolite relative to the flag threshold. The threshold flags are diagnostic limits to the data retrieved from each blood spot. The data includes metabolite concentrations and molar ratios of metabolites with other metabolites. Samples are labeled normal for a disease if the concentration of any of the metabolite concentrations or molar ratio concentration do not deviate from the flag threshold, but, in contrast, the sample must be further evaluated if a value is elevated or deficient to some degree. Thus, as each metabolite fragments at a different mass to charge value (m/z), corresponding ...

METHODS FOR DETECTING VITAMIN C BY MASS SPECTROMETRY

Provided are methods for determining the amount of vitamin C in a sample using mass spectrometry. The methods generally involve ionizing vitamin C in a sample and detecting and quantifying the amount of the ion to determine the amount of vitamin C in the sample. 1. A method for determining an amount of ascorbic acid (vitamin C) in a sample , the method comprising:(i) ionizing vitamin C in the sample by electrospray ionization (ESI) to generate at least one vitamin C ion detectable by mass spectrometry;(ii) determining the amount of the at least one vitamin C ion by tandem mass spectrometry;wherein the amount of vitamin C in the sample is determined from the amount of vitamin C ion(s) from step (ii).2. The method of claim 1 , wherein the ionizing is performed in positive ion mode.3. The method of claim 1 , further comprising purifying vitamin C in the test sample prior to mass spectrometry.4. The method of claim 3 , wherein the purifying comprises purifying with liquid chromatography.5. The method of claim 4 , wherein the liquid chromatography comprises high performance liquid chromatography (HPLC).6. The method of claim 1 , wherein the amount of vitamin C in the sample is determined using a calibration standard curve.7. The method of claim 1 , wherein the ions are detected by multiple reaction monitoring (MRM).8. The method of claim 1 , wherein the method has an extraction recovery of more than 80%.9. A method for determining an amount of ascorbic acid (vitamin C) in a sample claim 1 , the method comprising:(i) purifying vitamin C in the test sample by liquid chromatography;(ii) ionizing vitamin C in the sample by electrospray ionization (ESI) in positive ion mode to generate at least one vitamin C ion detectable by mass spectrometry;(iii) determining the amount of the at least one vitamin C ion by tandem mass spectrometry;wherein the amount of vitamin C in the sample is determined from the amount of vitamin C ion(s) from step (iii).10. The method of claim 9 , ...

PEPTIDES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR CELIAC SPRUE

COMPOSITIONS, DEVICES, AND METHODS OF OSTEOARTHRITIS SENSITIVITY TESTING

Contemplated test kits and methods for food sensitivity related to osteoarthritis are based on rational-based selection of food preparations with established discriminatory p-value. In some embodiments, kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤ 0.07 as determined by their raw p-value or an average discriminatory p-value of ≤ 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.

NS4 NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE FOR THE TREATMENT OF BODY WEIGHT DISORDERS

The present invention is directed to novel polypeptides NS4 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating body weight disorders (e.g, obesity, cachexia or anorexia) are provided.

A NOVEL BIOLOGICAL SUBSTANCE NESFATIN AND ITS RELATED SUBSTANCES AND USES THEREOF

A novel method for obtaining a factor involved in the control of food intake and/or body weight; a gene produced by the method, a polypeptide encoded by the gene or a novel peptide produced based on the information on the polypeptide encoded by the gene for use as a means for the treatment/control/diagnosis of a disease involving the eating disorder and/or body weight control; and a substance capable of inhibiting the action of the gene or polypeptide for use as a means for the treatment/control/diagnosis of a disease involving the control of food intake and/or body weight. A gene or polypeptide involved in the suppression of food intake and/or decrease in body weight can be produced by using a thiazolidione having a PPAR.gamma.-agonistic activity. NESFATIN or the like produced by the method can be used as a means for the treatment/control/diagnosis of a disease involving the eating disorder and/or body weight control.

COMPOSITIONS, DEVICES, AND METHODS OF DEPRESSION SENSITIVITY TESTING

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of = 0.07 as determined by their raw p-value or an average discriminatory p-value of = 0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value ...

测定血斑中血浆铜蓝蛋白浓度的方法及肝豆状核变性病筛选试剂盒和诊断试剂

... 本发明涉及测量全血浆铜蓝蛋白浓度的方法，特别涉及使用全血浆铜蓝蛋白特异性多克隆抗体和全血浆铜蓝蛋白特异性单克隆抗体，利用通过酶联免疫吸附测定法(enzyme-linked immunosorbent assay；ELISA)或解离强化的时间分辨荧光免疫测定法(dissociation-enhanced time-resolved fluoroimmunoassy)得到的标准浓度曲线，测定全血浆铜蓝蛋白浓度的方法。本发明还涉及肝豆状柱变性病筛选的试剂盒和诊断试剂。 ...

PRODUCTS AGONISTES OF TGR5 AND THEIR APPLICATIONS

NOVEL ANTI-AGING AGENTS AND METHODS TO IDENTIFY THEM

The present invention discloses novel mechanisms in the aging process and describes novel methods for high-throughput screening to identify, detect, and purify agents to be used for improving mitochondrial function, maintaining the cell cycle- arrested state in senescent and post mitotic cells, and thus preventing or treating age- related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions identified from this method. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders.

BIOMARKERS FOR APPETITE REGULATION

The invention provides compositions and methods for characterizing appetite regulation in a subject. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, total ghrelin, obestatin, cholecystokinin, GLP-1 (6-37)-NH2, NPY and α-MSH. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in characterizing appetite regulation. The invention also provides methods of treating a subject (e.g. one experiencing obesity) and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.

Anti-aging agents and methods to identify them

The present invention discloses novel mechanisms in the aging process and describes novel methods for high-throughput screening to identify, detect, and purify agents to be used for improving mitochondrial function, maintaining the cell cycle-arrested state in senescent and post mitotic cells, and thus preventing or treating age-related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions identified from this method. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders.

Kit and method for detecting food allergies

A method for detection of food allergies, by determining the presence of antibodies against specific antigens in a stool sample, involves diluting the specimen, introducing the diluted specimen to a substrate containing food antigens, and visually detecting a reaction.

Milk fat globule epidermal growth factor 8 regulates fatty acid uptake

Methods and compositions for regulating fatty acid uptake and/or decreasing gastric motility in an animal are provided. The method comprises administering an antagonist of integrin α v β 3 or α v β 5 to an animal in an amount sufficient to reduce fatty acid uptake in the animal, thereby reducing fatty acid uptake in the animal. In some embodiments, the antagonist is an antibody. Also provided is a method of increasing fatty acid uptake and/or gastric motility in an animal.

METHODS FOR EVALUATING RISK OF MOTHER'S MILK OR FOOD INDUCING AN ONSET OF ATOPIC DERMATITIS, AND MOTHER'S MILK OR FOOD WITH REDUCED RISK OF INDUCING AN ONSET OF ATOPIC DERMATITIS

An entity of a Th2 adjuvant activity in mother's milk has been revealed as coenzyme A by HPLC and mass spectrometry. The followings have been found out that: a risk of developing atopic dermatitis can be evaluated by targeting coenzyme A; and any one of a food and mother's milk with a reduced risk of developing atopic dermatitis can be prepared by removing or inactivating coenzyme A.

Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals

The present invention describes novel methods for diagnosis and treatment of conditions that alter phosphate transport in mammals. The fibroblast growth factor proteins and nucleotides that may be useful as a therapeutic or in the diagnosis of such conditions are also described.

Isolated antibodies against biologically active leptin-related peptides

The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass.

DIAGNOSTIC USE OF PROSOMATOSTATIN

Methods for diagnosing and treating obesity by modulating the activity of auto-antibodies against the melanocortin-4 receptor

Use of enterovirus for diagnostics, treatment and prevention of disease

METHOD FOR DIAGNOSING IMMUNOLOGIC FOOD SENSITIVITY

The invention includes novel methodology for diagnosing immunologic food or drug sensitivities. The method for diagnosing food sensitivities includes using diagnoses of other related disorders, such as microscopic colitis or other chronic immunologic/autoimmune syndromes, chronic diarrhea, irritable bowel syndrome, and hepatitis C and other hepatic diseases, Crohn's disease, alcoholism, and other idiopathic neuropsychiatric and neurologic disorders, as indicators in the diagnosis of the food sensitivity. Additionally, failure to respond to or a relapse after treatment for microscopic colitis with bismuth subsalicylate is disclosed by the present invention as being a further indicator in the diagnosis of immunologic food sensitivity. Finally, the presence of certain HLA-DQ alleles, particularly HLA-DQ1,3; -DQ1,7; -DQ1,8; and -DQ1,9, HLA-DQ1,1, and at least two subtypes of the HLA-DQ1 allele identified by molecular analysis as HLA-DQB1*0501 and HLA-DQB1*0602, as indicators in diagnosing immunologic ...

Breath ketone detector

Ketoacidosis is an extreme and uncontrolled form of ketosis, which is a normal response to prolonged fasting. Embodiments of this invention test the ketone level of a patient by measuring the ketone bodies in breath condensation. Some embodiments include a device for medical testing comprising a hollow container, comprising powder mixture of sodium nitroferricyanide, ammonium sulfate and silica and a liquid including an ammonium hydroxide solution.

Use of blood group status

The present invention relates to use of the non-secretor/secretor blood group status of an individual as a criterion for need of Lactobacillus /LAB-enriched probiotic supplementation. The present invention relates also to method of assessing the need of an individual for Lactobacillus /LAB-enriched probiotic supplementation by determining the secretory blood group status of the individual.

SYSTEMS AND METHODS FOR MONITORING OF BLOOD LACTATE AND TARGETING OF BLOOD LACTATE VIA NUTRITIONAL SUPPORT

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system. 1. A computer program product comprising a non-transitory computer readable medium having a computer readable program code embodied therein , the product being executable by a processor to perform a method of preventing or treating body wasting in a human patient with traumatic brain injury , the method comprising:receiving a blood lactate concentration of the patient, from a lactate analyzer that has analyzed a blood sample of the patient, the blood lactate concentration received directly from the lactate analyzer or indirectly from the lactate analyzer over a network; andadministering, based on the received blood lactate concentration of the patient, if the blood lactate concentration is less than about 2.0 mM, a nutritional support to the patient.2. The computer program product of wherein the nutritional support comprises a gluconeogenic precursor or a monocarboxylic compound or both.3. The computer program product of wherein the nutritional support comprises one or more salts.4. The computer program product of wherein the nutritional support has a milliosmolality of less than about 1000.5. The ...

INDOXYL SULFATE AS A BIOMARKER OF PREBIOTIC EFFICACY FOR WEIGHT GAIN PREVENTION

The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain. 1. A method for predicting and/or quantifying the response of a subject to prebiotics in the prevention of diet induced weight gain , comprisinga) determining a level of indoxyl sulfate in a urine sample obtained from a subject that has consumed prebiotics, andb) comparing the subject's indoxyl sulfate level to a predetermined reference value,wherein a decreased indoxyl sulfate level, or an absence of change in the indoxyl sulfate level, in the urine sample compared to the predetermined reference value indicates that the administration of prebiotics is effective in the prevention of diet induced weight gain in the subject.2. The method of claim 1 , wherein the diet is a high fat diet.4. The method according to claim 1 , wherein the levels of the biomarkers in the urine sample are determined by H-NMR and/or mass spectrometry.5. The method according to claim 1 , wherein the predetermined reference value is based on an average indoxyl sulfate level in urine in a control population of subjects consuming a high fat diet.6. The method according to claim 1 , wherein the predetermined reference value is the indoxyl sulfate level in urine in the subject before the prebiotics were consumed.7. The method according to claim 1 , wherein the level of indoxyl sulfate and/or the further biomarkers are determined in a urine sample obtained from the subject after at least three consecutive days of prebiotic consumption.8. The method according to claim 1 , wherein the prebiotic is selected from the group consisting of oligosaccharides claim 1 , optionally containing fructose claim 1 , galactose claim 1 , mannose; dietary fibers claim 1 , in particular soluble fibers claim 1 , soy fibers; inulin; or mixtures thereof.9. The method according to ...

Dermatopontin as a therapeutic for metabolic disorders

The present disclosure describes to a method of treating a metabolic disease in a subject, wherein the method comprises administration of dermatopontin to a subject, wherein the dermatopontin is recombinant dermatopontin and the metabolic disease is selected from a group consisting of weight gain, diet-induced weight gain, obesity, morbid obesity, metabolic syndrome, glucose homeostasis, insulin resistance, type I diabetes, type if diabetes and cardiovascular disease. Disclosed herein is also a method of determining or making a prognosis of a subject's susceptibility to metabolic diseases and obesity, the method comprising measuring the level of circulating dermatopontin in a sample obtained from a subject; and comparing the level of circulating dermatopontin obtained with the level of dermatopontin previously determined in a control; and determining the susceptibility of the subject to metabolic disease and obesity based on the difference between the level of circulating dermatopontin and the level of dermatopontin in the control.

METHOD FOR DETECTING TOTAL 25-HYDROXYVITAMIN D USING ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample. 1. A hybridoma cell that produces a monoclonal antibody that binds 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.2. A kit comprising an antibody , or an antigen-binding fragment thereof , that binds 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in a sample.3. The kit of further comprising an alkaline phosphatase-conjugated vitamin D-C22-bovine serum albumin (BSA). This application is a divisional of U.S. application Ser. No. 15/915,001 filed on Mar. 7, 2018 which is a continuation of U.S. application Ser. No. 14/335,686, filed on Jul. 18, 2014, which is a continuation of U.S. application Ser. No. 13/458,847, filed on Apr. 27, 2012, which claims priority to U.S. Provisional Application No. 61/488,630, filed on May 20, 2011. All of the applications mentioned in this paragraph are incorporated herein by reference in their entirety.Provided herein are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and ...

SYSTEMIC IMMUNE ACTIVATION AND BIOMARKERS OF NONCELIAC WHEAT/GLUTEN SENSITIVITY

The present invention provides a method of using increased levels of one or more biomarkers to identify subjects having non-celiac gluten sensitivity or non-celiac wheat sensitivity. The identification would aid the physician or health professional to determine a specific treatment for the patient, for example, a diet that eliminates wheat, rye, and/or barley. In one embodiment, the biomarkers are one or more of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2). The present invention also provides a method of using the same markers to monitor the response to treatment for non-celiac wheat sensitivity in a subject. 18-. (canceled)9. A method of treating a subject having non-celiac wheat sensitivity , comprising the steps of:i. determining blood levels of one or more markers in said subject, said markers are selected from the group consisting of soluble CD 14, lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2), wherein increased levels of said markers in said subject as compared to control levels indicate said subject has non-celiac wheat sensitivity; andii. treating the subject identified in (i) with a diet free of one or more of wheat, rye and barley.10. The method of claim 9 , wherein said control levels are derived from healthy subjects or subjects having celiac disease.11. The method of claim 9 , wherein levels of said markers are determined in serum or plasma.12. The method of claim 9 , wherein said anti-lipopolysaccharide antibodies are IgM antibodies.13. The method of claim 9 , wherein said anti-flagellin antibodies are one or both of IgM antibodies and IgG antibodies.14. The method of claim 9 , wherein said anti-gliadin antibodies are one or more of IgA claim 9 , IgM and IgG ...

Blood lactate range targets and nutritional formulations and protocols to support patients

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

DETECTION METHOD FOR QUATERNARY AMMONIUM COMPOUND HAVING y-CARBOXYL GROUP

The invention discloses a detection method for a quaternary ammonium compound having a γ-carboxyl group. The quaternary ammonium compound converts to a fluorophore labeled-quaternary ammonium compound; and therefore can be easily detected by reverse-phase liquid chromatography, fluorescence spectrometry or mass spectrometry. The invention also discloses a diagnostic method for carnitine deficiency which can be used to evaluate whether a suspected patient suffers from carnitine deficiency by measuring an L-carnitine amount in a sample obtained from the suspected patient utilizing said detection method. The invention further discloses a detection kit for the quaternary ammonium compound having the γ-carboxyl group which can be used for detecting the quaternary ammonium compound having the γ-carboxyl group in a sample. 1. A detection method for a quaternary ammonium compound having a γ-carboxyl group , comprising:mixing a sample including the quaternary ammonium compound having the γ-carboxyl group, a fluorescent compound having a fluorophore and a polar aprotic solvent to form a reaction solution;{'sub': '2', 'incubating the reaction solution at 80-120° C. for 1-15 minutes, assuring a SNnucleophilic substitution reaction occurs between the fluorophore of the fluorescent compound and the carboxyl group of the quaternary ammonium compound, to obtain a derivation solution includes a derivative which is a quaternary ammonium compound with the carboxyl group substituted with the fluorophore of the fluorescent compound; and'}detecting the derivative in the derivation solution as an analytic solution.2. The detection method for the quaternary ammonium compound having the γ-carboxyl group as claimed in claim 1 , wherein the method comprises: selecting 4-bromomethylbiphenyl claim 1 , 4-bromoethylbiphenyl claim 1 , 4-bromomethyl-2′-cyanobiphenyl claim 1 , (2-biphenyl)diazomethane claim 1 , 4-aminobiphenyl claim 1 , biphenyl-4-yl-hydrazine hydrochloride claim 1 , 4-phenylphenol ...

METHOD OF DIGITIZING NUTRITIONAL STATUS, MUSCLE TURNOVER, AND RISK ASSESSMENT

The present invention provides a method of digitizing nutritional status, muscle turnover, and risk assessment using the formulas containing four amino acids, which are Histidine, Leucine, Ornithine and Phenylalanine. The method of present invention can provide information regarding personalized nutritional status, muscle turnover and risk assessment, understand the effect of nutrition intervention, assist muscle growth and the effect of rehabilitation training, and improve patients' quality of life and bodily function. 2. The method of claim 1 , wherein the Formula 4 further determines the level of muscle lysis.3. The method of claim 1 , wherein the Formula 3 further determines liver metabolic function.4. The method of claim 1 , wherein the Formula 1 further determines muscle turnover.5. The method of claim 1 , wherein the Formula 5 further determines metabolite loading to liver.6. The method of claim 1 , wherein the biological sample of the step (a) is blood claim 1 , plasma claim 1 , serum claim 1 , red blood cells or urine.7. The method of claim 1 , wherein the subject of the step (a) is a patient suffering from a disease or a healthy normal person.8. The method of claim 7 , wherein the disease is aging claim 7 , cancer claim 7 , chronic diseases claim 7 , severe diseases or cardiovascular diseases.9. The method of claim 8 , wherein the chronic disease is chronic obstructive pulmonary disease (COPD) claim 8 , end stage of renal disease (ESRD) or chronic kidney disease (CKD).10. The method of claim 1 , wherein the detecting method of the step (a) is a mass spectrometry (MS) claim 1 , liquid chromatograph (LC) claim 1 , micro-scale capillary electrophoresis or high performance capillary electrophoresis.11. The method of claim 1 , wherein adjusting the subject's nutrition intervention and lifestyle according to result of the step (c).12. The method of claim 11 , wherein the step (a) to the step (c) are done again after adjusting the nutrition intervention and ...

Methods for Diagnosing Impaired Absorption of Amino Acids, Monosaccharides and Fatty Acids

Provided herein are methods for diagnosing impaired nutrient absorption or determining a nutrient absorption level in an individual. A first stable absorption isotopologue of a nutrient and a second stable absorption isotopologue of the same nutrient are administered orally and intravenously, respectively, to the individual. Amounts of the first and second isotopologues are both measured in blood samples drawn periodically and a ratio of the first isotopologue to the second isotopologue is calculated providing a level of nutrient absorption. The results are compared with a healthy control or an ideal value of 1.0. The ratio less than that of a healthy control or significantly lower than 1.0 indicates an impaired nutrient absorption in the individual. 1. A method for diagnosing impaired absorption of a nutrient in an individual , comprising the steps of:administering a first stable absorption isotopologue of said nutrient orally to the individual;administering a second stable absorption isotopologue of the same nutrient intravenously to said individual;drawing blood samples periodically from said individual;measuring an amount of the first isotopologue and of the second isotopologue in each sample;calculating a ratio of the first isotoologue to the second isotopologue in each sample; andcomparing the ratio calculated for the individual to a ratio calculated for a healthy control; wherein, when the ratio calculated for the individual is less than the ratio for the healthy control, impaired absorption of the nutrient in said individual is present.2. The method of claim 1 , further comprising:analyzing the nutrient production, consumption and metabolism; andproducing a metabolic phenotype based on the analysis.3. The method of claim 2 , wherein the individual has chronic heart failure claim 2 , chronic obstructive pulmonary disease claim 2 , a cancer claim 2 , a cognitive dysfunction claim 2 , or is a bariatric pre-operative or post-operative patient.410. The method of ...

Continuous monitoring of blood lactate and ongoing targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

METHOD FOR EVALUATING IN VIVO PROTEIN NUTRITION BASED ON LC-MS-MS TECHNIQUE

Disclosed is a method for evaluating in vivo protein nutrition based on an LC-MS-MS technique, including the following steps: (1) collecting contents from different intestinal segments, and extracting and isolating protein ingredients; (2) determining the concentration of proteins; (3) treating before carrying out mass spectrometry: including digestion and desalting of a whole protein solution; (4) LC-MS-MS analysis; (5) database searching; and (6) data processing. Proteomic technology is used to identify proteins in the contents of different intestinal segments and digestive products thereof, and the source of the proteins in the contents of different intestinal segments and the contents thereof can be determined therefrom. Through bioinformatic analysis, the function of differential proteins in the body can be further understood, where the gene expression of enzymes related to protein digestion and metabolism may be different, thereby providing a scientific basis for further scientific evaluation of protein digestion and utilization. 1. A method for evaluating in vivo protein nutrition based on an LC-MS-MS technique , comprising of the following steps:(1) collecting contents from different intestinal segments, and extracting and isolating protein ingredients;(2) determining the concentration of proteins;(3) treating before carrying out mass spectrometry: including digestion, desalting and blow-drying of a whole protein solution;(4) LC-MS-MS analysis: a peptide product is obtained by carrying out reversed phase liquid chromatography using a nanoliquid chromatograph mass spectrometer on the digested, desalted and blow-dried samples, and analysis is performed by a nanoliter ion source by tandem mass spectrometry using an LTQ-Orbitrap mass spectrometer;(5) database searching: MaxQuant_1.5.8.3 software is used to search for 30 individual original spectral files running on a shotgun LC-MS/MS, respectively;(6) data processing: databases are searched from three aspects ...

SYSTEMS AND METHODS FOR MONITORING OF BLOOD LACTATE AND TARGETING OF BLOOD LACTATE VIA NUTRITIONAL SUPPORT

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system. 1. A system for treating body wasting in a human patient with traumatic brain injury , the system comprising:means for analyzing a blood lactate concentration of the patient; and{'b': 2', '0, 'means for administering a nutritional support to the patient, based on the blood lactate concentration of the patient, if the blood lactate concentration is less than about . mM.'}2. The system of wherein the nutritional support comprises a gluconeogenic precursor or a monocarboxylic compound or both.3. The system of wherein the nutritional support comprises one or more salts.41000. The system of wherein the nutritional support has a milliosmolality of less than about .5. The system of wherein the nutritional support comprises an amino acid.6. The system of wherein the nutritional support comprises one or more of the following: glycerol claim 1 , glycerol tri-lactate claim 1 , glycerol tri-acetate claim 1 , arginyl lactate claim 1 , lactate N-acetylcysteine ester claim 1 , pyruvate claim 1 , acetoacetate claim 1 , or beta-hydroxy butyrate.7145. The system of wherein the nutritional support is administered at ...

METHODS FOR DETECTING VITAMIN C BY MASS SPECTROMETRY

Provided are methods for determining the amount of vitamin C in a sample using mass spectrometry. The methods generally involve ionizing vitamin C in a sample and detecting and quantifying the amount of the ion to determine the amount of vitamin C in the sample. 1. A method for determining an amount of vitamin C in a test sample by mass spectrometry , the method comprising:(i) ionizing vitamin C in the test sample to generate at least one vitamin C ion detectable by mass spectrometry;(ii) determining the amount of the at least one vitamin C ion by mass spectrometry; and(iii) using the amount of vitamin C ion(s) from step (ii) to determine the amount of vitamin C in the test sample.2. The method of claim 1 , wherein the ionizing is performed in negative ion mode.3. The method of claim 1 , wherein the ionizing comprises ionizing by atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI).4. The method of claim 1 , wherein the ionizing comprises generating one or more precursor ion of the vitamin C with a mass/charge ratio of 175.05±0.5.5. The method of claim 1 , wherein the ionizing comprises generating one or more fragment ions comprising a mass/charge ratio of 114.85±0.5 or 86.85±0.5.6. The method of claim 1 , wherein the mass spectrometry is tandem mass spectrometry.7. The method of claim 1 , further comprising purifying vitamin C in the test sample prior to mass spectrometry.8. The method of claim 7 , wherein the purifying comprises purifying with liquid chromatography.9. The method of claim 8 , wherein the liquid chromatography comprises high performance liquid chromatography (HPLC).10. The method of claim 8 , wherein the liquid chromatography comprises high turbulence liquid chromatography (HTLC) or both.11. The method of claim 7 , wherein the purifying comprises protein precipitation.12. The method of claim 1 , wherein the test sample is plasma or serum.13. The method of claim 1 , further comprising adding a stabilizing agent to the test ...

ENERGY MALNUTRITION EVALUATION FOR LIVER DISEASE TEST SUBJECT

A method for measuring energy malnutrition in a liver disease test subject, a method for determining whether a liver disease test subject is in an energy malnutrition state, a method for determining the necessity of nutrition therapy for a liver disease test subject having energy malnutrition, a composition usable in these methods, and the like are provided. The method for measuring energy malnutrition in a liver disease test subject includes the steps of collecting expired air containing labeled carbon dioxide that is generated in the body of a liver disease test subject by being converted from a composition containing, as an active ingredient, glucose labeled with at least one isotope C; and determining the ratio of labeled COamount to unlabeled COamount, or the ratio of labeled COamount to total COamount in expired air. 1. A method for determining the necessity of a nutrition therapy for a liver disease test subject having energy malnutrition , comprising steps (A) and (B) below:{'sub': 2', '2', '2', '2, '(A) determining the ratio of labeled COamount to unlabeled COamount, or the ratio of labeled COamount to total COamount in collected expired air, the expired air being excreted from the body of a liver disease test subject and containing labeled carbon dioxide that is generated in the body by being converted from a composition containing, as an active ingredient, glucose labeled with at least one isotope C; and'}{'sub': 2', '2', '2', '2', '2', '2', '2', '2, '(B) comparing “the ratio of labeled COamount to unlabeled COamount, or the ratio of labeled COamount to total COamount in the expired air” (subject value) obtained in step (A) with “the ratio of labeled COamount to unlabeled COamount, or the ratio of labeled COamount to total COamount in the expired air” in healthy subject (control value), thereby determining whether the subject value is lower than the control value.'}2. The method according to claim 1 , further comprising step (C) below:(C) excluding one or ...

A METHOD FOR DETERMINING MYELOID NATURAL KILLER (NK)-CELLS AND USE THEREOF

The present invention relates to ex-vivo methods for determining myeloid NK-cells, methods for diagnosis of a disease associated with and/or caused by myeloid NK-cells as well as depletion of myeloid NK-cells for use in treating. The present is also related to methods for determining whether a candidate agent reduces a myeloid NK-cell population. 1. An ex-vivo method for determining myeloid NK-cells comprising the steps of:a) providing a sample containing myeloid NK-cells;b) marking the myeloid NK-cells of the sample by means of at least one marking reagent; andc) detecting the myeloid NK-cells,wherein the myeloid NK-cells are characterized by the expression of cell surface marker phenotypical for NK-cells and by an expression of Il6ra.2. The method of claim 1 , further comprising a step b′) after the step b)b′) separating the marked myeloid NK-cells from the sample.3. The method of claim 1 , further comprising a step d) after the step c):d) quantifying the marked myeloid NK-cells.4. The method of claim 1 , wherein the myeloid NK-cells are mature myeloid NK-cells.5. The method of claim 1 , wherein the myeloid NK-cells are further characterized by an expression of cell Csf11r.6. The method of claim 1 , wherein the myeloid NK-cells are further characterized by an activation of Stat3.7. The method of claim 1 , wherein the myeloid NK-cells are characterized by upregulation Il6ra and of at least 50% of the genes selected from the following group consisting of Pla2g7 claim 1 , Fos claim 1 , Csf1r claim 1 , Cd93 claim 1 , Mpegl claim 1 , Cybb claim 1 , Ctss claim 1 , Spi1 claim 1 , Cd74 claim 1 , Plbd1 claim 1 , Cd14 claim 1 , Clec10a claim 1 , Il1rn claim 1 , Sirpa claim 1 , Pid1 claim 1 , Ptafr claim 1 , Ly86 claim 1 , Grn claim 1 , Tgfbi claim 1 , Ctsh claim 1 , C1qc claim 1 , C1qb claim 1 , Mrc1 claim 1 , Lrp1 claim 1 , Csf2ra claim 1 , Ncf1 claim 1 , Cxcl9 claim 1 , Cd302 claim 1 , Cd300lb claim 1 , Nfam1 claim 1 , Trem2 claim 1 , Emilin2 claim 1 , App claim 1 , Sdc3 ...

METHODS FOR DETECTING VITAMIN C BY MASS SPECTROMETRY

Provided are methods for determining the amount of vitamin C in a sample using mass spectrometry. The methods generally involve ionizing vitamin C in a sample and detecting and quantifying the amount of the ion to determine the amount of vitamin C in the sample. 1. A method for determining an amount of ascorbic acid (vitamin C) in a sample , the method comprising:(i) extracting vitamin C by high turbulence liquid chromatography;(ii) ionizing vitamin C in the sample by atmospheric pressure chemical ionization (APCI) in negative ion mode to generate at least one vitamin C ion with a mass/charge ratio of 114.85±0.50 and/or 86.85±0.50 that is detectable by mass spectrometry;(iii) determining the amount of the at least one said vitamin C ion by tandem mass spectrometry;wherein the amount of vitamin C in the sample is determined from the amount of vitamin C ion(s) from step (iii).2. The method of claim 1 , wherein the method further comprises high performance liquid chromatography (HPLC).3. The method of claim 1 , wherein the amount of vitamin C in the sample is determined using a calibration standard curve.4. The method of claim 1 , wherein the ions are detected by multiple reaction monitoring (MRM).5. A method for determining an amount of ascorbic acid (vitamin C) in a sample claim 1 , the method comprising:(i) purifying vitamin C in the test sample by high turbulence liquid chromatography (HTLC) followed by high performance liquid chromatography (HPLC);(ii) ionizing vitamin C in the sample by atmospheric pressure chemical ionization (APCI) in negative ion mode to generate at least one vitamin C ion with a mass/charge ratio of 114.85±0.50 and/or 86.85±0.50 that is detectable by mass spectrometry;(iii) determining the amount of the at least one said C ion by tandem mass spectrometry;wherein the amount of vitamin C in the sample is determined from the amount of vitamin C ion(s) from step (iii).6. The method of claim 5 , wherein the amount of vitamin C in the sample is ...

Lipids That Increase Insulin Sensitivity And Methods Of Using The Same

The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, Metabolic Syndrome, polycystic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.

Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.

METHOD OF PREDICTING OBESITY

The presently disclosed subject matter relates to a method for predicting increased risk of obesity on a non-obese subject. More particularly, the presently disclosed subject matter relates to a method of predicting increased risk of obesity in a non-obese subject by determining a level of neurotensin expression in a biological sample from the subject and comparing the level of neurotensin expression in the sample with a control level. The presently disclosed subject matter further relates to a method of preventing and/or treating obesity in a subject in need thereof by administering to the subject an effective amount of an agent that inhibits neurotensin. 1. A method of predicting increased risk of obesity in a non-obese subject , comprising:contacting a biological sample from the subject with a probe for neurotensin to determine the amount of neurotensin in the biological sample;comparing the amount of neurotensin to a control level; anddetermining that the subject has an increased risk of obesity if there is a measurable difference in the amount of neurotensin in the sample as compared to control level, wherein an increased neurotensin level is predictive of an increased risk of becoming obese.2. The method of claim 1 , further comprising:measuring the phosphorylation level of AMPK in the biological sample; andcomparing the measured phosphorylation level to a control level, wherein a decreased level of phosphorylation level is predictive for an increased risk of becoming obese.3. The method of claim 1 , wherein the neurotensin is pro-neurotensin.4. The method of claim 1 , wherein the risk of becoming obese is independent of baseline body mass index.5. The method of claim 1 , wherein the biological sample comprises blood claim 1 , plasma claim 1 , serum claim 1 , plasma claim 1 , and tissue.6. The method of claim 1 , wherein the amount of pro-neurotensin is detected by a technique comprising RNA measuring assays and protein measuring assays.7. The method of claim ...

QUANTIFICATION OF A CHANGE IN ASSAY

The present invention relates to portable devices for point-of-care diagnostics that can perform measurements on a sample (e.g., blood, serum, saliva, or urine) and relay data to an external device for, e.g., data analysis. The device can comprise a paper-based diagnostic substrate and a base substrate that include electronic circuitry and electronic elements necessary for performing the measurements. The device can also comprise an antenna for near field communication with an external device. Another aspect of the invention relates to methods of using these devices. 1. A measurement device comprising:a diagnostic substrate comprising (a) a sample receiver to receive a sample, wherein the sample receiver is at least partially formed in or disposed on the diagnostic substrate; (b) a fluidic channel connected to the sample receiver; (c) a detection region at least partially formed in or disposed on the diagnostic substrate, wherein the detection region is coupled to the sample receiver by the fluidic channel; (d) a control region at least partially formed in or disposed on the diagnostic substrate, wherein the control region is coupled to the detection region by the fluidic channel, anda base substrate comprising (e) an antenna for near-field communication (NFC) at least partially formed in or disposed on the base substrate; (f) electronic circuitry connected to the antenna and at least partially formed in or disposed on the base substrate, wherein the electronic circuitry generates data as a function of an output signal from the sample or a derivative thereof; (g) a first portion comprising a first photodetector and a second photodetector connected to the electronic circuitry and at least partially formed in or disposed on the first portion; (h) a second portion comprising a first light source and a second light source connected to the electronic circuitry and at least partially formed in or disposed on the second portion, wherein the first portion and the second ...

COMPOSITIONS, DEVICES, AND METHODS OF GASTROESOPHAGEAL REFLUX DISEASE SENSITIVITY TESTING

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value. 1. A gastroesophageal reflux disease test kit panel consisting essentially of:a plurality of distinct gastroesophageal reflux disease food preparations immobilized to an individually addressable solid carrier;wherein the plurality of distinct gastroesophageal reflux disease food preparations each have a raw p-value of ≤0.07 or a false discovery rate (FDR) multiplicity adjusted p-value of ≤0.10.2. The test kit panel of wherein the plurality of distinct gastroesophageal reflux disease food preparations includes at least two food preparations selected from the group consisting of sunflower seed claim 1 , chocolate claim 1 , tobacco claim 1 , malt claim 1 , cane sugar claim 1 , almond claim 1 , barley claim 1 , rye claim 1 , green pepper claim 1 , cola nut claim 1 , green pea claim 1 , broccoli claim 1 , buck wheat claim 1 , cantaloupe claim 1 , orange claim 1 , oyster claim 1 , oat claim 1 , safflower claim 1 , walnut claim 1 , baker's yeast claim 1 , cauliflower claim 1 , cinnamon claim 1 , lemon claim 1 , sweet potato claim 1 , mustard claim 1 , lima bean claim 1 , grapefruit claim 1 , corn claim 1 , string bean claim 1 , brewer's yeast claim 1 , cabbage and honey.3. (canceled)4. The test kit panel of wherein the plurality of distinct gastroesophageal reflux disease food preparations includes at least eight food preparations.5. The test kit panel of wherein the plurality of distinct gastroesophageal ...

Lateral flow immunoassay for detecting vitamins

The invention is directed to a method for detecting analytes, particularly vitamins, using a lateral flow immunoassay. The method may be used to detect vitamin D, particularly 25-hydroxy vitamin D 3 or 1,25-dihydroxy vitamin D 3 . The method involves obtaining a fluid sample from a subject; applying the sample to a lateral flow test strip comprising a conjugate pad capable of releasing a labelled antibody against vitamin D, and a detection membrane comprising a first capture reagent specific to the antibody and immobilized on a test band; and detecting the presence or absence of vitamin D in the sample. The presence of a detectable signal in the test band is indicative of vitamin D deficiency.

Method for modulating appetite

The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1 modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.

BACTERIAL INFLUENCE ON REGULATION OF APPETITE VIA CLPB PROTEIN MIMICRY OF ALPHA-MSH

The present invention relates to bacterial Clp B protein and Clp B expressing bacteria and their impact on eating disorders. The invention further relates to compositions comprising antibiotic directed against at least one Clp B expressing bacterium as well as probiotics not expressing Clp B protein and their use in the treatment or prevention of eating disorders. The invention also relates to diagnostic tools for determining whether a subject is likely to respond to a method of treating eating disorders and to methods of immunization against eating disorders. 113-. (canceled)14. A method of treating or preventing eating disorders , or of reducing the chances of occurrence of eating disorders , or of regulating appetite in a subject , comprising administering to said subject a composition comprising at least one antibiotic directed against at least one ClpB protein expressing bacterium or administering to said subject a composition comprising probiotics not expressing ClpB protein.15. The method according to claim 14 , wherein the eating disorder is selected from the group consisting of anorexia nervosa (AN) claim 14 , bulimia nervosa (BN) claim 14 , binge eating disorder (BED) claim 14 , overeating claim 14 , hyperphagia claim 14 , wasting diseases such as cachexia.16. The method according to claim 14 , wherein said method is for treating or preventing eating disorders in a subject and wherein said method comprises administering to said subject a composition comprising at least one antibiotic directed against at least one ClpB protein expressing bacterium.17. The method according to claim 14 , wherein said method is for regulating appetite in a subject claim 14 , and wherein said method comprises administering to said subject an effective amount of a composition comprising at least one antibiotic directed against at least one ClpB protein expressing bacterium.18. The method according to claim 14 , wherein said method is for reducing the chances of occurrence of ...

Methods of Detecting Anti-folic acid Antibodies and Uses Thereof

The invention relates to devices and methods for detecting the presence of antibodies to folic acid in a sample. 1. A device for detecting anti-folic acid antibodies comprising: a folic acid component and a substrate , wherein the folic acid component is attached to the substrate.2. The device of claim 1 , wherein the folic acid component is selected from the group consisting of folic acid claim 1 , a folic acid protein conjugate a fragment of folic acid claim 1 , an analog of folic acid claim 1 , a substituted version of folic acid claim 1 , a derivative of folic acid claim 1 , a fused combination of folic acid and a salt of folic acid.3. The device of claim 2 , wherein the folic acid component comprises a folic acid protein conjugate selected from the group consisting of folic acid conjugated to keyhole limpet hemocyanin (KLH) claim 2 , a fragment of folic acid conjugated to KLH claim 2 , and folic acid conjugated to biotin.47.-. (canceled)8. The device of claim 1 , wherein the substrate is selected from the group consisting of a bead and a well of a microtiter plate.9. (canceled)10. A method of detecting an anti-folic acid antibody in a sample claim 1 , comprising the steps ofa.) obtaining a sample;b.) contacting the sample with a component that binds to an anti-folic acid antibody; andc.) detecting binding between the anti-folic acid antibody and the component.11. The method of claim 10 , wherein the component is selected from the group consisting of folic acid claim 10 , a folic acid protein conjugate claim 10 , a fragment of folic acid claim 10 , an analog of folic acid claim 10 , a substituted version of folic acid claim 10 , a derivative of folic acid claim 10 , a fused combination of folic acid and a salt of folic acid.12. The method of claim 10 , wherein the method of detecting the binding comprisesa.) contacting a complex formed by the binding of the anti-folic acid antibody to the component with a labeled biomolecule capable of specifically binding to ...

MILK FAT GLOBULE EPIDERMAL GROWTH FACTOR 8 REGULATES FATTY ACID UPTAKE

Methods and compositions for regulating fatty acid uptake and/or decreasing gastric motility in an animal are provided. 1. A method of increasing fatty acid uptake and/or decreasing gastric motility in an animal , the method comprising ,administering a polypeptide comprising (i) Milk Fat Globule Epidermal Growth Factor 8 (Mfge8), or (ii) an integrin-binding portion of Mfge8, to an animal in an amount sufficient to increase fatty acid uptake and/or to decrease gastric motility in the animal.2. The method of claim 1 , wherein the Mfge8 is human Mfge8 (SEQ ID NO:1) or is at least 80% identical to (i) SEQ ID NO:1 or (ii) an integrin-binding portion of SEQ ID NO:1.3. The method of claim 1 , wherein the animal is human4. The method of claim 3 , wherein the animal is under two or one years or under six claim 3 , five claim 3 , four claim 3 , three claim 3 , two claim 3 , or one months old.5. The method of claim 1 , wherein the animal is a premature human infant.6. The method of claim 1 , wherein the animal is diabetic or has cystic fibrosis.7. The method of claim 1 , wherein the polypeptide is administered intravenously claim 1 , subcutaneously claim 1 , intramuscularly claim 1 , rectally claim 1 , or orally.8. The method of claim 7 , wherein the polypeptide is administered as a component of a composition selected from the group consisting of a powder claim 7 , a tablet claim 7 , a capsule claim 7 , a lozenge claim 7 , a chewing gum claim 7 , a food product claim 7 , a supplemented beverage claim 7 , or a medical food.9. The method of claim 8 , wherein the food product is infant formula.10. A composition comprising a polypeptide comprising (i) Milk Fat Globule Epidermal Growth Factor 8 (Mfge8) claim 8 , or (ii) an integrin-binding portion of Mfge8.11. The composition of claim 10 , wherein the Mfge8 is human Mfge8 (SEQ ID NO:1) or is at least 80% identical to (i) SEQ ID NO:1 or (ii) an integrin-binding portion of SEQ ID NO:1.12. The composition of claim 10 , wherein the ...

METHOD FOR DETERMINING THE DISTINCTIVE NUTRITIONAL REQUIREMENTS OF A PATIENT

The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient. 1. An in vitro method for determining the distinctive disease related nutritional requirements of a subject suffering from a disease characterized by distinctive nutritional requirements in the diseased subject over a healthy subject comprising the steps:a. determining in a sample of a subject suffering from the disease a profile of statuses of markers indicating the nutritional profile of said subject;b. determining in a sample of a healthy subject a profile of the statuses of the same markers determined in step a; andc. comparing the profiles determined in step a. and b., and thereby determining the distinctive nutritional requirements for nutrients in a patient suffering from the disease.2. The method of claim 1 , wherein the disease is inflammatory bowel disease.3. The method of claim 1 , wherein the nutrients are selected from the group consisting of proteins claim 1 , amino acids claim 1 , fats claim 1 , carbohydrates claim 1 , and micronutrients.4. The method according to claim 1 , wherein in step 1 a) the status of the markers is determined in a cohort of subjects.5. The method according to claim 1 , wherein in step 1 b) the status of the markers is determined in a cohort of healthy subjects.6. The method according to claim 1 , wherein the sample is a sample selected from the group consisting of whole blood claim 1 , blood plasma claim 1 , blood serum claim 1 , red blood cells claim 1 , urine claim 1 , and tissue biopsies.7. The method according to where the status of the markers is measured by directly quantifying the marker or indirectly by quantifying a further marker or markers indicating the status of said first marker.8. Method according to claim 1 , wherein the status of at least 10 markers is determined.9. The method ...

Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.

METHOD FOR DETERMINING THE DISTINCTIVE NUTRITIONAL REQUIREMENTS OF A PATIENT

The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient. 130-. (canceled)31. A method for manufacturing a nutritional composition for administration to a subject suffering from a disease characterized by distinctive nutritional requirements in the subject over a healthy subject , the method comprising:a. determining in a sample of the subject suffering from the disease a profile of statuses of markers comprising direct and indirect markers indicating the nutritional profile of the subject, wherein each of the direct markers indicates an amount of a macronutrient or micronutrient, and each of the indirect markers are derived from the direct markers by quantifying a corresponding direct marker and quantifying one or more additional markers that indicate a status of the corresponding direct marker, at least one of the direct and indirect markers is selected from the group consisting of an amino acid marker, a fat marker, a carbohydrate marker, a nucleotide marker, an osmolyte marker, a peptide marker, a catabolism marker, a nitric synthase marker, and combinations thereof;b. determining in a sample of the healthy subject a profile of the statuses of the same markers comprising the same direct and indirect markers determined in step a, at least one of the sample of the subject suffering from the disease or the sample of the healthy subject is a sample selected from the group consisting of whole blood, blood plasma, blood serum, red blood cells, urine, tissue biopsies, and combinations thereof;c. comparing the profiles determined in steps a. and b., and determining distinctive nutritional requirements for nutrients comprising macronutrients and micronutrients in the subject suffering from the disease based on the comparison of the profiles determined in steps a. and b., wherein when a level of ...

A method for determining myeloid natural killer (nk)-cells and use thereof

The present invention relates to ex-vivo methods for determining myeloid NK-cells, methods for diagnosis of a disease associated with and/or caused by myeloid NK-cells as well as depletion of myeloid NK-cells for use in treating. The present is also related to methods for determining whether a candidate agent reduces a myeloid NK-cell population.

Bispecific anti-ctla4/anti-pd-1 antibody and its use

anticorpo biespecífico anti-ctla4/anti-pd-1 e uso do mesmo. a presente invenção refere-se ao campo de tratamento de tumores e imunologia molecular e, particularmente, a um anticorpo biespecífico anti-ctla4/anti-pd-1 e uso do mesmo. especificamente, o anticorpo bifuncional anti-ctla4/anti-pd-1 compreende uma primeira região funcional de proteína direcionada a pd-1 e uma segunda região funcional de proteína direcionada a ctla4, em que, de acordo com o sistema de numeração eu, a região constante da cadeia pesada da imunoglobulina compreendida no anticorpo biespecífico tem mutações em quaisquer 2 ou 3 das posições 234, 235 e 237, e a constante de afinidade do anticorpo biespecífico para fc¿riiia e/ou c1q é reduzida após a mutação em comparação com aquela antes da mutação. o anticorpo bifuncional da presente invenção pode se ligar bem e especificamente a ctla4 e pd-1, aliviar especificamente a imunossupressão de ctla4 e pd-1 em um organismo e ativar linfócitos t, tendo assim uma boa perspectiva de aplicação. bispecific anti-ctla4/anti-pd-1 antibody and use thereof. The present invention relates to the field of tumor treatment and molecular immunology, and particularly to an anti-α4/anti-pd-1 bispecific antibody and use thereof. specifically, the bifunctional anti-ctla4/anti-pd-1 antibody comprises a first functional region of pd-1-targeted protein and a second functional region of ctla4-targeted protein, wherein, according to the eu numbering system, the immunoglobulin heavy chain constant region comprised in the bispecific antibody has mutations at any 2 or 3 of positions 234, 235 and 237, and the affinity constant of the bispecific antibody for fc¿riiia and/or c1q is reduced after the mutation compared to the one before the mutation. The bifunctional antibody of the present invention can bind well and specifically to ctla4 and pd-1, specifically alleviate the immunosuppression of ctla4 and pd-1 in an organism and activate t-lymphocytes, thus having a good prospect of ...

A kind of retinol binding protein measures test kit and method of testing thereof

本发明公开了一种采用磁微粒化学发光法测定中视黄醇结合蛋白(RBP)含量的试剂盒。试剂盒包括校准品、质控品、抗试剂、磁微粒试剂、发光底物；其中抗试剂异硫氰酸荧光素标记的视黄醇结合蛋白包被抗体和碱性磷酸酶标记的视黄醇结合蛋白标记抗体；磁微粒试剂为磁微粒与羊抗FITC连接物。本发明将化学发光技术与免疫磁微粒相结合，提供了一种接近均相的反应体系，并且采用了一步法反应模式，使得检测灵敏度、精密性大大提高、检测范围扩大，反应时间大大缩短，从开始加样到检测结果，时间少于25min,明显快于同类试剂盒；并且可以在全自动化学发光仪上同时测定多个样本，实现视黄醇结合蛋白的高通量快速化测定，准确度高，特异性强，精确度和检测效率有了较大的提高。

Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof

비타민 D 유도체, 예를 들어, 25-하이드록시비타민 D2 및/또는 25-하이드록시비타민 D3, 또는 25-하이드록시비타민 D 유사체, 예를 들어, 비타민 D-C22 면역원성 분자 또는 화합물에 결합할 수 있는 항체를 발생시키기 위해 사용될 수 있는 항원성 분자가 본원에 제공된다. 상기 항원성 분자, 및 관련 항원성 화합물을 이용하여 생성된 항체가 또한 기재된다. 또한, 피검체에서 비타민 D 결핍을 검출하기 위한 방법. 비타민 D 결핍을 갖는 것으로 여겨지는 피검체를 치료하기 위한 방법, 피검체에서 비타민 D 결핍의 진행을 모니터하기 위한 방법, 및 비타민 D 결핍의 치료를 모니터할 필요가 있는 피검체에서 비타민 D 결핍의 치료를 모니터하기 위한 방법이 본원에 개시된다. 25-하이드록시비타민 D2 및 D3의 검출 또는 정량을 위한 방법 및 시약, 비타민 D 유사체를 안정화시키기 위한 방법, 및 생물학적 샘플에서 비타민 D 결합 단백질로부터 25-하이드록시비타민 D2 및 D3를 분리시키기 위한 방법이 또한 제공된다. Vitamin D derivatives such as 25-hydroxyvitamin D2 and / or 25-hydroxyvitamin D3, or 25-hydroxyvitamin D analogs, such as vitamin D-C22 immunogenic molecules or compounds Provided herein are antigenic molecules that can be used to generate antibodies that are present. Also described are antibodies generated using such antigenic molecules, and related antigenic compounds. Also, a method for detecting vitamin D deficiency in a subject. A method for treating a subject believed to have a vitamin D deficiency, a method for monitoring the progress of a vitamin D deficiency in a subject, and treatment of a vitamin D deficiency in a subject in need of monitoring the treatment of a vitamin D deficiency Disclosed herein are methods for monitoring. Methods and reagents for the detection or quantification of 25-hydroxyvitamins D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamins D2 and D3 from vitamin D binding proteins in biological samples Also provided.

Novel physiological substance nesfatin, substance relevant thereto, and use of the substances

Whole blood assay for measuring ampk activation

A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.

Deficiency in the histone demethylase jhdm2a results in impaired energy expenditure and obesity

The present invention relates to animal models of metabolic disorders such as obesity, diabetes, metabolic syndrome, insulin resistance, hyperinsulinemia, glucose intolerance, hyperlipidemia, and the like. In particular, the invention relates to transgenic non-human animals having a reduction in functional Jhdm2a gene expression and use of such animals and cells having reduced Jhdm2a expression in drug discovery. The invention further relates to the identification of subjects having or at increased risk for developing a metabolic disorder based on a genetic marker in the Jhdm2a gene.

NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders

The present invention is directed to novel polypeptides NS4 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating body weight disorders (e.g., obesity, cachexia or anorexia) are provided.

Selenoprotein P as a marker for selenium poisoning

Die vorliegende Erfindung bezieht sich auf Verfahren zum Bewerten des Grades der Se-Intoxikation in einer Testperson durch Bestimmen eines gemessenen SePP-Wertes und Korrelieren des Messwertes mit einer Selen-IntoxikationsKlassifizierungskategorie; und einen oder mehrere Gesundheitszustandsparameter der Testperson; und/oder einen oder mehrere krankheitsspezifische Parameter der Testperson und die Verwendung der Verfahren bei der Analyse und Überwachung von Selenvergiftungen, therapeutischer Se-Supplementierung und von Tierfutter. The present invention relates to methods of assessing the degree of Se intoxication in a test subject by determining a measured SePP value and correlating the measured value with a selenium intoxication classification category; and one or more health status parameters of the subject; and / or one or more disease-specific parameters of the test person and the use of the method in the analysis and monitoring of selenium poisoning, therapeutic Se supplementation and animal feed.

Bioactive composition, process for its production and biological application

一つ以上の植物から、抽出によって、生物活性な組成物を得る方法であって、 ａ）粗製完全抽出物、または有効成分に富むフラクション、より具体的には無極性フラクションまたは極性フラクション、を得るために、所与の活性に関して選択した植物またはそれらの部分を別々に、一つ以上の溶媒で処理する工程と、 ｂ）ＭＴＴ試験に対して代謝活性を示し、そしてその活性の、少なくとも一つの特異的な試験に対して生物活性を示す抽出物またはフラクションを選択する工程と を含む方法である。

Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof

本文提供了可用于产生能够结合维生素D衍生物，例如25-羟基维生素D2和/或25-羟基维生素D3，或25-羟基维生素D类似物，例如维生素D-C22免疫原性分子或化合物的抗体的抗原性分子。还描述了使用这些抗原分子和相关抗原性化合物产生的抗体。另外，本文公开了用于检测受试者中维生素D缺乏的方法、用于治疗怀疑具有维生素D缺乏的受试者的方法、用于监测受试者中维生素D缺乏进展的方法和用于监测需要其的受试者中维生素D缺乏的治疗的方法。还提供用于25-羟基维生素D2和D3的检测或定量的方法和试剂，用于稳定化维生素D类似物的方法，和用于从生物样品中维生素D结合蛋白分离25-羟基维生素D2和D3的方法。

Methods for diagnosing and treating obesity by modulating the activity of auto-antibodies against the melanocortin-4 receptor

Disclosed are biological markers for obesity and methods for diagnosing and treating obesity and related conditions by detecting and modulating the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor. Also disclosed are methods for discovering new therapeutics which modulate the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor, in particular which prevent the binding of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor.

Methods for detecting vitamin c by mass spectrometry

Provided are methods for determining the amount of vitamin C in a sample using mass spectrometry. The methods generally involve ionizing vitamin C in a sample and detecting and quantifying the amount of the ion to determine the amount of vitamin C in the sample.

Method for diagnosing immunologic food sensitivity

The invention includes novel methodology for diagnosing immunologic food or drug sensitivities. The method for diagnosing food sensitivities includes using diagnoses of other related disorders, such as microscopic colitis or other chronic immunologic/autoimmune syndromes, chronic diarrhea, irritable bowel syndrome, and hepatitis C and other hepatic diseases, Crohn's disease, alcoholism, and other idiopathic neuropsychiatric and neurologic disorders, as indicators in the diagnosis of the food sensitivety. Additionally, failure to respond to or a relapse after treatment for microscopic colitis with bismuth subsalicylate is disclosed by the present invention as being a further indicator in the diagnosis of immunologic food sensitivity. Finally, the presence of certain HLA-DQ alleles, particularly HLA-DQ1,3; -DQ1,7; -DQ1,8; and -DQ1,9, HLA-DQ1,1, and at least two subtypes of the HLA-DQ1 allele identified by molecular analysis as HLA-DQB1*0501 and HLA-DQB1*0602, as indicators in diagnosing immunologic food sensitivity, particularly gluten sensitivity or celiac sprue, and in diagnosing the related disease of microscopic colitis and other autoimmune disorders is also disclosed by the invention. A method for food sensitivity panel testing (for sensitivities other than gluten sensitivity) by detecting IgA antibodies in serum is also disclosed. A method for testing stool samples for the presence of particular antibodies, which is more sensitive and less invasive than prior art testing methods, is also disclosed for diagnosing immunologic food sensitivities. These methods of diagnosis may be used alone or in combination to further enhance the accuracy of diagnosis.

Indoxyl sulfate as a biomarker of prebiotic efficacy for preventing weight gain

Novel anti-aging agent and method to identify them

本发明发现了衰老过程的新机制，并建立了一种高通量筛选方法来筛选鉴别，检测和提纯的试剂，用于改善线粒体功能的使用，在不分裂细胞和分裂静止细胞中维持不分裂状态，预防或治疗与的线粒体功能加速丧失、染色体端粒功能异常和不分裂细胞死亡有关的老年性疾病。本发明也披露了用此方法筛选出来的一系列化合物或组合物构成。本发明进一步提供了低剂量雷帕霉素或它的衍生物作为热量限制模仿物在防治老年性疾病上的用途。

Whole blood test to measure AMPK activation

Un método para evaluar el estado de energía de un sujeto que comprende: a) marcar células de una muestra sanguínea del sujeto usando un anticuerpo que se une específicamente con fosfo- AMPK, fosfo-acetil-CoA carboxilasa o fosfo-HMG-CoA reductasa, para producir una muestra marcada; y b) medir la unión de anticuerpo con células individuales de una población de células sanguíneas de dicha muestra marcada usando citometría de flujo, obteniendo de este modo una evaluación de la activación de AMPK de dicha población de células, en la que la activación de AMPK evaluada en dicha población de células puede usarse para evaluar el estado de energía del sujeto. A method of assessing the energy status of a subject comprising: a) marking cells from a blood sample from the subject using an antibody that specifically binds with phospho-AMPK, phospho-acetyl-CoA carboxylase or phospho-HMG-CoA reductase, to produce a marked sample; and b) measuring the binding of antibody with individual cells of a population of blood cells of said labeled sample using flow cytometry, thereby obtaining an evaluation of the activation of AMPK of said population of cells, in which the activation of AMPK evaluated in said cell population can be used to assess the energy status of the subject.

Use of blood group status IV

Means and procedures for determining a standard amount of clearance of a biomarker of metabolic disease in a sample

Un procedimiento para determinar una cantidad normalizada de aclaramiento de un biomarcador de enfermedad metabólica en un tipo de muestra que comprende las etapas de: (a) determinar la cantidad del biomarcador de enfermedad metabólica en dicho tipo de muestra de un sujeto del que se sospecha que padece la enfermedad; (b) determinar la cantidad de un biomarcador de función renal que se correlaciona con la tasa de filtración glomerular (TFG) en el mismo tipo de muestra; y (c) determinar una cantidad normalizada de aclaramiento para el biomarcador de enfermedad metabólica normalizando la cantidad determinada para el biomarcador de enfermedad metabólica en la etapa (a) con respecto a la cantidad del biomarcador de función renal determinada en la etapa (b), en el que dicho tipo de muestra es sangre o un derivado de la misma. A method for determining a standard amount of clearance of a biomarker of metabolic disease in a type of sample comprising the steps of: (a) determining the amount of the biomarker of metabolic disease in said type of sample of a subject suspected of being suffer from the disease; (b) determine the amount of a biomarker of renal function that correlates with the glomerular filtration rate (GFR) in the same type of sample; and (c) determine a standard amount of clearance for the metabolic disease biomarker by normalizing the amount determined for the metabolic disease biomarker in stage (a) with respect to the amount of the biomarker of renal function determined in stage (b), wherein said type of sample is blood or a derivative thereof.

diagnostic use of pro-somatostatin

resumo patente de invenção: "uso diagnóstico de pró-somatostatina". a presente invenção refere-se a um método para o diagnóstico, prognóstico, monitoramento e avaliação do risco de distúrbios da atividade e/ou função do trato gastrointestinal e/ou distúrbios da condição nutricional, com a exceção de somatostatinoma, em um paciente compreendendo as etapas de: fornecimento de uma amostra de um fluido corporal de um paciente, determinação do nível de pró-somatostatina 1-64 ou fragmentos da mesma na referida amostra; correlação do nível de pró-somatostatina 1-64 ou fragmentos da mesma com o diagnóstico, prognóstico e avaliação do risco de distúrbios da atividade e/ou função do trato gastrointestinal e/ou distúrbios da condição nutricional, com a exceção de somatostatinoma, no referido paciente, em que os referidos fragmentos têm um comprimento de pelo menos 6 resíduos de aminoácidos. a invenção refere-se também a um anticorpo e um kit contendo pelo menos dois anticorpos. patent summary: "diagnostic use of prosomatostatin". The present invention relates to a method for the diagnosis, prognosis, monitoring and assessment of the risk of gastrointestinal tract activity and / or function disorders and / or nutritional condition disorders, with the exception of somatostatinoma, in a patient comprising the steps of: providing a sample of a patient's body fluid, determining the level of prosomatostatin 1-64 or fragments thereof in said sample; correlation of pro-somatostatin level 1-64 or fragments thereof with the diagnosis, prognosis and risk assessment of gastrointestinal tract activity and / or function disorders and / or nutritional status disorders, with the exception of somatostatinoma, in that patient, wherein said fragments are at least 6 amino acid residues in length. The invention also relates to an antibody and a kit containing at least two antibodies.

Compositions, devices, and methods of gastroesophageal reflux disease sensitivity testing.

La presente invención se refiere a kits y métodos de prueba contemplados para la sensibilidad a los alimentos basados en una selección de base racional de preparaciones alimenticias con un valor p discriminatorio establecido. Los kits particularmente preferidos incluyen aquellos con un número mínimo de preparaciones alimenticias que tienen un valor de p discriminatorio promedio de = 0.07 determinado por su valor de p bruto o un valor p discriminatorio promedio de = 0.10 según lo determinado por el valor p ajustado por la multiplicidad de FDR. En otros aspectos adicionales contemplados, las composiciones y los métodos para la sensibilidad a los alimentos también se estratifican por género para mejorar además el valor predictivo.

Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity

The invention relates to a method and novel types of agents for modulating appetite and/or body weight in a subject. Moreover, the invention relates to a method of screening for agents which interact and modulate the activity of the receptor complex for macrophage inhibitory cytokine-1 (MIC-1).

Anti-ctla4/anti-pd-1 bispecific antibody and use thereof

Provided are an anti-CTLA4-anti-PD-1 bispecific antibody and uses thereof. The bispecific antibody comprises: a first protein functional area targeting PD-1 and a second protein functional area targeting CTLA4, where, according to the EU numbering system, the constant region of an immunoglobulin heavy chain is mutated at any two loci or three loci of locus 234, locus 235, and locus 237, and after the mutation, the affinity constant of the bispecific antibody with Fc?RIIIa and/or C1q is reduced compared to that before the mutation. The bispecific antibody is capable of specifically binding with CTLA4 and PD-1, disabling the immunosuppression of CTLA4 and PD-1 with respect to the body, and activating T lymphocytes, and is applicable in preventing, treating, or diagnosing a tumor or anemia.

Selenoprotein P as marker of selenium intoxication

本发明涉及通过确定SePP的测量值并且将所述测量值与硒中毒分级类别；所述受试者的一种或多种健康状况参数；和/或所述受试者的一种或多种疾病特异性参数关联来评价受试者Se中毒的等级的方法，以及该方法在硒中毒的分析和监测、治疗性Se补充和动物饲料中的用途。

Anti aging agents and methods to identify them

The present invention discloses novel mechanisms in the aging process and describes novel methods for high-throughput screening to identify, detect, and purify agents to be used for improving mitochondrial function, maintaining the cell cycle-arrested state in senescent and post mitotic cells, and thus preventing or treating age-related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions identified from this method. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders.

Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity

The invention relates to a method and novel types of agents for modulating appetite and/or body weight in a subject. Moreover, the invention relates to a method of screening for agents which interact and modulate the activity of the receptor complex for macrophage inhibitory cytokine-1 (MIC-1).

Auto-antibodies against the melanocortin-4 receptor

Disclosed are biological markers for obesity and methods for diagnosing and treating obesity and related conditions by detecting and modulating the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor. Also disclosed are methods for discovering new therapeutics which modulate the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor, in particular which prevent the binding of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor.

Method of measuring ceruloplasmin concentration in a blood spot, kit and method of diagnosing Wilson's disease

The present invention relates to a method for measuring a ceruloplasmin concentration, and more particularly, to a method for measuring a ceruloplasmin in a blood spot based on a standard concentration curve obtained through an enzyme-linked immunosorbent assay (ELISA) or a dissociation-enhanced time-resolved fluoroimmunoassay using a ceruloplasmin-specific polyclonal antibody or a ceruloplasmin-specific monoclonal antibody.

Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample

The present invention relates to a method for determining a clearance normalized amount of a metabolite disease biomarker in a sample comprising the steps of (a) determining the amount of the disease biomarker in at least a first type of sample of a subject suspected to suffer from the disease, (b) determining the amount of a kidney function biomarker which correlates with the glomerular filtration rate (GFR) in the said at least first type of sample, and (c) determining a clearance normalized amount for the metabolite disease biomarker by normalizing the amount determined for the metabolite disease biomarker in step (a) to the amount of the kidney function biomarker determined in step (b). Moreover, the invention also relates to a method for diagnosing a disease in a subject suspected to suffer therefrom and to a device for determining a clearance normalized amount of a metabolite disease biomarker in a sample.

Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25- hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.

Method to modulate the appetite

Agente de inhibición de MIC-1 que disminuye el nivel en suero o actividad de MIC-1 endógena, para uso en un método para incrementar el peso corporal y/o apetito en un sujeto que padece pérdida de peso y/o disminución del apetito debida a la sobreexpresión de MIC-1 asociada con la inflamación, lesión, estrés, radioterapia o quimioterapia, en el que dicho agente de inhibición se selecciona de un anticuerpo anti-MIC-1 o un fragmento de unión a MIC-1 del mismo.

Modulation of peripheral clocks in adipose tissue

Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same

This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in human proteolytical system such as serine and cysteine proteases and their inhibitors and pharmaceutical agents and other therapies affecting these. This invention discloses methods for the treatment and prevention of cardiovascular diseases such as coronary heart disease (CHD), acute myocardial infarction (AMI), chronic CHD, arterial hypertension (HT) and cerebrovascular stroke and metabolic disorders such as the metabolic syndrome (MBO) and obesity and methods for detecting or diagnosing a risk of, or predisposition to the said diseases in a subject, for selecting treatment in a subject and for selecting subjects for studies testing cardiovascular, anti-diabetic and anti-obesity drugs, as well as to transgenic animals.

Method for measuring fat free body weight

本发明涉及一种用于测定儿科个体的去脂体重(FFM)的水平的方法，所述方法包括测定从所述个体获得的样本中苯乙酰谷氨酰胺(PAG)的水平。

Biomarkers for appetite regulation

The invention provides compositions and methods for characterizing appetite regulation in a subject. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, total ghrelin, obestatin, cholecystokinin, GLP-1 (6-37)-NH 2 , NPY and α-MSH. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in characterizing appetite regulation. The invention also provides methods of treating a subject (e.g. one experiencing obesity) and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.

NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders

The present invention is directed to novel polypeptides NS4 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating body weight disorders (e.g., obesity, cachexia or anorexia) are provided.

Method for determining fat free body mass

Method of measuring ceruloplasmin concentration in a blood spot, kit and method of diagnosing wilson's disease

The present invention relates to a method for measuring a ceruloplasmin concentration, and more particularly, to a method for measuring a ceruloplasmin in a blood spot based on a standard concentration curve obtained through an enzyme-linked immunosorbent assay (ELISA) or a dissociation-enhanced time-resolved fluoroimmunoassay using a ceruloplasmin-specific polyclonal antibody or a ceruloplasmin-specific monoclonal antibody.

Tetrahydro-isoalpha acid compositions and methods for weight management

Compositions and methods to promote or maintain weight loss utilizing tetrahydro-isoalpha acid compounds are disclosed. Methods to increase synthesis of GLP-1 are disclosed.

Categorically ranking animals for feed efficiency

The invention provides methods for managing livestock for breeding or production based on one or more measurements of mitochondrial function. Measurement of mitochondrial function may also be correlated with a calculated or known feed efficiency of livestock animals to yield a predicted feed efficiency for the animal. The invention overcomes deficiencies associated with phenotypic assays for predicted breeding and production value.

METHOD FOR THE DIAGNOSIS OF IMMUNOLOGICAL FOOD SENSITIVITY

Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample

Whole blood assay for measuring ampk activation

A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.

Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto

The invention relates to methods and compositions for the modulation of glucose homeostasis and/or the treatment of metabolic diseases. In some embodiments, the invention relates to methods and compositions for the modulation of histone deacetylases. such as Class Ila histone deacetylases.

Prophylactic/therapeutic agents for lifestyle-related diseases

Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the level of expression of mRNA for a prostate-specific antigen or the level of production of the prostate-specific antigen in the prostate cancer cell; and contacting the substance with an adipocyte and measuring the level of expression of mRNA for uncoupling protein-1 or the level of production of uncoupling protein-1 in the adipocyte. Also disclosed is a selective androgen receptor modulator comprising a compound represented by any one formula selected from the structural formulae (I) to (III) as an active ingredient. Further disclosed is a composition for preventing or treating lifestyle-related diseases, which comprises the selective androgen receptor modulator.

Method for interpreting tandem mass spectrometry data for clinical diagnosis

A method for interpreting data that is produced after a group of amino acids and acylcarnitines are derivatized from blood spots taken from newborn babies and scanned by a tandem mass spectrometer. Concentration levels of each metabolite, which are directly proportional to the butyl ester fragment after derivatization, are compared to threshold flags for determining a significance of any deviation of the metabolite relative to the flag threshold. The threshold flags are diagnostic limits to the data retrieved from each blood spot. The data includes metabolite concentrations and molar ratios of metabolites with other metabolites. Samples are labeled normal for a disease if the concentration of any of the metabolite concentrations or molar ratio concentration do not deviate from the flag threshold, but, in contrast, the sample must be further evaluated if a value is elevated or deficient to some degree. Thus, as each metabolite fragments at a different mass to charge value (m/z), corresponding data is compared to the respective flag thresholds for determining a next course of action that must be taken to ultimately assist a physician in the diagnosis of a genetic disorder resulting from an elevation or deficiency of the metabolite particular for that disorder.

Prognostic allergy or inflammation test

One can predict the likelihood a child will outgrow an allergy, especially a food allergy, by screening for IgE antibodies immunoreactivities with linear versus conformational epitopes. The child is first screened using standard techniques to determine what antigens the child is allergic to. The immunoglobulins in the sample from the patient are then characterised either using the natural purified antigen, recombinant antigen, reduced and alkylated antigen, proteolytic fragments of the antigen or synthetic peptides of between 4 and 40 amino acids in length, which can be immobilised for rapid and accurate screening. The antibodies from the patient are reacted with the protein or peptides to determine which peptides are bound by the antibodies. These antibodies are then characterised to determine if the epitopes they bind are linear or conformational. Those patients having antibodies primarily reactive with conformational epitopes will typically outgrow their allergies. A similar method for evaluation of IgG antibodies can be used to predict the prognosis of certain inflammatory disorders.

Method for diagnosing immunologic food sensitivity

The invention includes novel methodology for diagnosing immunologic food or drug sensitivities. The method for diagnosing food sensitivities includes using diagnoses of other related disorders, such as microscopic colitis or other chronic immunologic/autoimmune syndromes, chronic diarrhea, irritable bowel syndrome, and hepatitis C and other hepatic diseases, Crohn's disease, alcoholism, and other idiopathic neuropsychiatric and neurologic disorders, as indicators in the diagnosis of the food sensitivity. Additionally, failure to respond to or a relapse after treatment for microscopic colitis with bismuth subsalicylate is disclosed by the present invention as being a further indicator in the diagnosis of immunologic food sensitivity. Finally, the presence of certain HLA-DQ alleles, particularly HLA-DQ1,3; -DQ1,7; -DQ1,8; and -DQ1,9, HLA-DQ1,1, and at least two subtypes of the HLA-DQ1 allele identified by molecular analysis as HLA-DQB1*0501 and HLA-DQB1*0602, as indicators in diagnosing immunologic food sensitivity, particularly gluten sensitivity or celiac sprue, and in diagnosing the related disease of microscopic colitis and other autoimmune disorders is also disclosed by the invention. A method for food sensitivity panel testing (for sensitivities other than gluten sensitivity) by detecting IgA antibodies in serum is also disclosed. A method for testing stool samples for the presence of particular antibodies, which is more sensitive and less invasive than prior art testing methods, is also disclosed for diagnosing immunologic food sensitivities. These methods of diagnosis may be used alone or in combination to further enhance the accuracy of diagnosis.

Methods for detecting vitamin C by mass spectrometry

Provided are methods for determining the amount of vitamin C in a sample using mass spectrometry. The methods generally involve ionizing vitamin C in a sample and detecting and quantifying the amount of the ion to determine the amount of vitamin C in the sample.

A method for determining myeloid natural killer (nk)-cells and use thereof

The present invention relates to ex-vivo methods for determining myeloid NK-cells, methods for diagnosis of a disease associated with and/or caused by myeloid NK- cells as well as depletion of myeloid NK-cells for use in treating. The present is also related to methods for determining whether a candidate agent reduces a myeloid NK-cell population.